Patent Grant
10588544
There are many instances in both medical and non-medical applications where one desires to note a personal event, i.e., an event that is specific to a given individual. Examples of medical applications where one may wish to note an event that is specific to a given individual include, but are not limited to, the onset of one or more physiological parameters of interest, including disease symptoms, the administration of a medication, etc. Examples of non-medical applications where one desires to note an event that is specific to a given individual include, but are not limited to: the ingestion of certain types of foods, e.g., for individuals on controlled diets, the commencement of an exercise regimen, etc.
Because there are many instances where one wishes to note a personal event, a variety of different methods and technologies have been developed to make such notation possible. For example, log books and techniques have been developed in which individuals, e.g., patients and/or their health care provides, can record, e.g., by manually writing or data entry, time and date of an event.
However, there continues to be a need for improvements in personal event monitoring. For example, manually logging when an event takes place can be time consuming and prone to error.
Event markers, e.g., ingestible event markers, having high reliability are provided. Aspects of the event markers include a support, a control circuit physically associated with the support to control the highly reliable event marker, a first electrochemical material physically associated with the support and electrically coupled to the control circuit, a second electrochemical material electrically coupled to the control circuit and physically associated with the support at a location different from the location of the first material, such that the first and second electrochemical materials are electrically isolated from each other; and a membrane physically associated to the support and positioned relative to the first electrochemical and second electrochemical materials to generate a virtual dipole length larger than an actual dipole length defined by the first and the second electrochemical materials.
Event markers, e.g., ingestible event markers (“IEMs”, sometimes referred to herein as “identifiers”), having high reliability are provided. Aspects of the ingestible event markers include a support, a control circuit physically associated with the support to control the highly reliable event marker, a first electrochemical material physically associated with the support and electrically coupled to the control circuit, a second electrochemical material electrically coupled to the control circuit and physically associated with the support at a location different from the location of the first material, such that the first and second electrochemical materials are electrically isolated from each other; and a membrane physically associated to the support and positioned relative to the first electrochemical and second electrochemical materials to generate a virtual dipole length larger than an actual dipole length defined by the first and the second electrochemical materials.
Ingestible Event Markers
As summarized above, ingestible event markers (IEMs) of the invention are highly reliable. By “highly reliable” is meant that the ingestible event markers of the invention correctly generate and transmit a signal when employed in an application for which they are intended at a frequency of 80% or greater, such as 90% or greater, including 95% or greater. Highly reliable ingestible event markers of the invention may correctly generate and transmit a signal at a frequency of 99.5% or greater, such as 99.9% or greater, and in some instances correctly generate and transmit a signal at a frequency of 100%. As further developed below, the highly reliable characteristic of the ingestible event markers may arise from one or more components and/or structural features of the IEM, as described in greater detail below. As reviewed in greater detail below, one or more components and/or structural features of the IEM may impart to the IEM one or more of the following characteristics: enhanced signal strength, extended lifetime, enhanced wetting by stomach fluid, reduced propensity for blockage by GI lining, reduced propensity of blockage by bubbles and/or anti-foaming, reduced propensity for floating, as compared to a suitable control. These desirable characteristics may be imparted to a given IEM by one or more structural features and/or chemical constituents, as reviewed in greater detail below.
An ingestible event marker is a device that is dimensioned to be ingestible and includes an IEM made up of an IEM circuitry component and a membrane. The IEM may also include a vehicle. A pharmaceutically active agent may be present in the membrane and/or vehicle. As the IEMs are dimensioned to be ingestible, in certain instances they are sized so that they can be placed in a human mouth and swallowed. In some instances, IEMs of the invention have a longest dimension that is 30 mm or less, such as 20 mm or less, including 5 mm or less.
Various aspects of event markers, e.g., ingestible event markers, of interest are described in PCT application serial no. PCT/US2006/016370 published as WO/2006/116718; PCT application serial no. PCT/US2007/082563 published as WO/2008/052136; PCT application serial no. PCT/US2007/024225 published as WO/2008/063626; PCT application serial no. PCT/US2007/022257 published as WO/2008/066617; PCT application serial no. PCT/US2008/052845 published as WO/2008/095183; PCT application serial no. PCT/US2008/053999 published as WO/2008/101107; PCT application serial no. PCT/US2008/056296 published as WO/2008/112577; PCT application serial no. PCT/US2008/056299 published as WO/2008/112578; and PCT application serial no. PCT/US2008/077753 published as WO2009/042812; the disclosures of which are herein incorporated by reference. In certain aspects, the ingestible event markers are disrupted upon administration to a subject. As such, in certain aspects, the compositions are physically broken, e.g., dissolved, degraded, eroded, etc., following delivery to a body, e.g., via ingestion, injection, etc. The compositions of these aspects are distinguished from devices that are configured to be ingested and survive transit through the gastrointestinal tract substantially, if not completely, intact.
Highly Reliable Event Marker
In various aspects, the highly reliable event marker includes a support, a control circuit physically associated with the support to control the highly reliable event marker, a first electrochemical material physically associated with the support and electrically coupled to the control circuit, a second electrochemical material electrically coupled to the control circuit and physically associated with the support at a location different from the location of the first material, such that the first and second electrochemical materials are electrically isolated from each other; and a membrane physically associated to the support and positioned relative to the first electrochemical and second electrochemical materials to generate a virtual dipole length larger than an actual dipole length defined by the first and the second electrochemical materials.
The highly reliable event marker may be configured to be activated upon contact with fluid at the target site, such as a conducting fluid, e.g., a stomach fluid, providing, for example, a voltage potential difference. In various aspects, the control circuit controls the conductance through logic that alters the overall impedance of the system. The control circuit, for example, may be electrically coupled to a clock. The clock may provide a clock cycle to the control circuit. Based upon the programmed characteristics of the control circuit, when a set number of clock cycles have passed, the control circuit alters the conductance characteristics between electrochemical materials. This cycle may be repeated and thereby the control circuit may produce a unique current signature characteristic, sometimes referred to herein as a “current signature”. The control circuit may also be electrically coupled to a memory. Both the clock and the memory may be powered by the voltage potential created between the materials when in contact with a conducting fluid.
With respect to current signatures, the current signatures may distinguish one class of highly reliable event marker from other types or may be universally unique, such as where the current signature is analogous to a human fingerprint which is distinct from any other fingerprint of any other individual and therefore uniquely identifies an individual on a universal level. In various aspects, the control circuit may generate a variety of different types of communications, including but not limited to: RF signals, magnetic signals, conductive (near field) signals, acoustic signals, etc.
Receivers, as heretofore described in various aspects of the present invention, do not require any additional cable or hard wire connection between the device and a receiver of the communication, sometimes referred to herein as a detector.
In some instances, the highly reliable event marker includes two dissimilar electrochemical materials which serve as a cathode and an anode. When the two dissimilar electrochemical materials come in contact with the body fluid, such as stomach fluid, a potential difference (voltage) is generated between the cathode and the anode as a result of the respective oxidation and reduction reactions occurring at the two dissimilar electrochemical materials. The dissimilar electrochemical materials making up the electrochemical materials can be made of any two materials appropriate to the environment in which the IEM circuitry component will be operating. The active materials are any pair of materials with different electrochemical potentials. The electrochemical material materials may be chosen to provide for a voltage upon contact with the target physiological site that is sufficient to drive a signal generation element of the IEM circuitry component. Where desired, the voltage provided by the two dissimilar electrochemical materials upon contact of the metals of the power source with the target physiological site is 0.001 V or higher, including 0.01 V or higher, such as 0.1 V or higher, e.g., 0.3 V or higher, including 0.5 volts or higher, and including 1.0 volts or higher, where in certain aspects, the voltage ranges from about 0.001 to about 10 volts, such as from about 0.01 to about 10 V.
Anode materials of interest include, but are not limited to: magnesium, zinc, sodium, lithium, iron and alloys thereof, e.g., Al and Zn alloys of Mg, which may or may not be intercalated with a variety of materials such, as graphite with Li, K, Ca, Na, Mg, and the like. Cathode materials of interest include, but are not limited to, copper salts, such as copper salts of iodide, chloride, bromide, sulfate, formate, Fe3+ salts, e.g., orthophosphate, pyrophosphate, etc. One or both of the metals may be doped with a non-metal, for example to enhance the voltage output of a partial power source or a battery. Non-metals that may be used as doping agents in certain aspects include, but are not limited to: sulfur, iodine and the like. In certain aspects, the electrochemical material materials are cuprous iodine (CuI) or cuprous chloride (CuCl) as the anode and magnesium (Mg) metal or magnesium alloy as the cathode. Aspects of the present invention use electrochemical material materials that are not harmful to the human body. When the materials are exposed and come into contact with the body fluid, such as stomach acid or other types of fluid (either alone or in combination with a dried conductive medium precursor), a potential difference, that is, a voltage, is generated between the electrochemical materials as a result of the respective oxidation and reduction reactions incurred to the two electrochemical material materials. A voltaic cell, or battery, can thereby be produced. Accordingly, in embodiments of the invention, such power supplies are configured such that when the two dissimilar materials are exposed to the target site, e.g., the stomach, the digestive tract, etc., a voltage is generated.
Electrochemical material materials of interest include those that generate substantially little, if any, gaseous bubbles upon contact with an aqueous physiological fluid, such as stomach acid. Electrochemical material materials of interest include metal alloys, where alloys of interest include, but are not limited to, alloys of Mg, Zn, Al, and Li. When present, the amount of metal alloy may range from 0.01 to 15, such as 0.1 to 15 including 1 to 15% by weight. One or more different alloy elements may be present in the alloy. Of interest in some aspects are “bubble-free” Mg alloys which are MgAl or MgZn alloys, such as but not limited to: AZ31 magnesium alloy, AZ61 magnesium alloy, and the like.
Highly reliable event markers, e.g., IEMs, may include a solid support. In certain aspects, the solid support is small, e.g., where it is dimensioned to have a width ranging from about 0.01 mm to about 20 mm, e.g., from about 0.1 mm to about 10 mm, including from about 0.5 mm to about 2 mm; a length ranging from about 0.01 mm to about 20 mm, e.g., from about 0.1 mm to about 20 mm, including from about 0.5 mm to about 2 mm, and a height ranging from about 0.01 mm to about 10 mm, e.g., from about 0.05 mm to about 2 mm, including from about 0.1 mm to about 0.5 mm. The solid support element may take a variety of different configurations, such as but not limited to: a chip configuration, a cylinder configuration, a spherical configuration, a disc configuration, etc, where a particular configuration may be selected based on intended application, method of manufacture, etc. While the material from which the solid support is fabricated may vary considerably, in certain aspects the solid support is made up of a semiconductor material, e.g., silicon.
The phrase “single integrated circuit” refers to a single circuit structure that includes all of the different desired functional blocks for the device. In these aspects, the integrated circuit is a monolithic integrated circuit (also known as IC, microcircuit, microchip, silicon chip, computer chip or chip) that is a miniaturized electronic circuit (which may include semiconductor devices, as well as passive components) that has been manufactured in the surface of a thin substrate of semiconductor material. The integrated circuits of certain aspects of the present invention may be hybrid integrated circuits, which are miniaturized electronic circuits constructed of individual semiconductor devices, as well as passive components, bonded to a substrate or circuit board.
IEMs may be fabricated using any convenient protocol. IEM fabrication protocols of interest include, but are not limited to, those described in PCT application serial no. PCT/US2006/016370 published as WO/2006/116718; PCT application serial no. PCT/US2007/082563 published as WO/2008/052136; PCT application serial no. PCT/US2007/024225 published as WO/2008/063626; PCT application serial no. PCT/US2007/022257 published as WO/2008/066617; PCT application serial no. PCT/US2008/052845 published as WO/2008/095183; PCT application serial no. PCT/US2008/053999 published as WO/2008/101107; PCT application serial no. PCT/US2008/056296 published as WO/2008/112577; PCT application serial no. PCT/US2008/056299 published as WO/2008/112578; and PCT application serial no. PCT/US2008/077753, the disclosures of which are herein incorporated by reference.
A given IEM may include a single IEM, or two or more IEMs, such as three or more, four or more, five or more, six or more, seven or more, eight or more, nine or more, or ten or more IEMs.
In some instances, an IEM may include a swellable or water-absorbing coating that serves to control the microenvironment of the IEM in a desired manner. Of interest in certain instances as swellable coatings are hydrogel coatings. Hydrogel coatings are polymeric coatings made up of one or more different types of non-water soluble polymers, where the coatings absorb water upon contact with an aqueous medium to produce a hydrated gel-structure that has a high water content, such as 90% or more w/w, including 95% or more w/w, such as 99% or more w/w. Any physiologically acceptable hydrogel composition may be employed as a coating, where hydrogel compositions of interest may include one or more of the following polymers: polyethylene oxides, acetates, etc. In some instances, the hydrogel coating may include one or more agents which provide for a controlled environment (for example in terms of conductivity or pH) when the ingestible event marker reaches the target physiological site. Agents of interest include, but are not limited to: salts of physiologically acceptable electrolytes, such as but not limited to: sodium ion, chloride ion, potassium ion and calcium ion, magnesium ion, etc. Specific physiologically compatible salts of interest include, but are not limited to: KCl, NaCl, MgCl2, and the like. Desired pH may range from 1 to 8, such as 2 to 7, and may be imparted by the presence of any suitable buffering agent.
Coatings may take a variety of different configurations, such as layers, snap-fit pre-made capsule components, etc. When present, coatings may cover only a portion of the ingestible event marker envelope the entire device. The coating may be uniform in terms of thickness.
Membrane
IEMs may include at least a pair of signal transmission elements, e.g., in the form of first and second electrochemical materials, which have an actual dipole length. Also present is a membrane which, for example, produces a virtual dipole length between the pair of transmission elements that is larger than the actual dipole length. In addition to controlling the magnitude of the current path between the materials, a membrane (sometimes referred to herein as “amplifier”) is used to increase the “length” of the current path and, hence, act to boost the conductance path, as disclosed in the U.S. patent application Ser. No. 12/238,345 entitled, “In-Body Device with Virtual Dipole Signal Amplification” filed Sep. 25, 2008, and in the U.S. patent application Ser. No. 12/564,017 entitled, “Communication System with Partial Power Source” filed Sep. 21, 2009 the entire content of which are incorporated herein by reference. Alternatively, throughout the disclosure herein, the terms “membrane”, and “amplifier” are interchangeably with the term “current path extender” without impacting the scope or the present aspects and the claims herein. While the length of the virtual dipole provided by the membrane may vary, in certain instances the length of the virtual dipole is two or more times, such as three or more times, e.g., five or more times, twenty or more times, etc., longer than the length of the actual dipole that exists between the pair of transmission elements. As the length of an actual dipole in a given IEM may vary, ranging in certain instances from 100 μm to 2 cm, such as 300 μm to 1 mm, the length of the virtual dipole may range, in certain instances, from 200 μm to 20 cm, such as 600 μm to 20 mm. In addition to the IEMs of the invention further include a membrane, where the membrane includes a pharmaceutically active agent.
The membrane may have a variety of different configurations, so long as it serves to provide a virtual dipole having a length that is longer than that of the actual dipole length between two or more of, such as a pair of, of signal transmission elements. In certain aspects, the membrane is a structure that is positioned between the pair of signal transmission elements. The membrane may have a two-dimensional or three-dimensional configuration, and may have any convenient shape, such as square, disc, triangular, ovoid, irregular, etc., as developed in greater detail below. The length of the virtual dipole provided by the signal amplification element is, in certain instances, dependent on the particular shape of the signal amplification element. For example, where the signal amplification element has a disc configuration, as developed in greater detail below, the length of the virtual dipole is substantially the same as, if not identical to, the radius of the disc.
The pair of transmission elements are, in certain instances, a pair of electrochemical materials positioned on opposing sides of a solid support, e.g., where the solid support comprises an integrated circuit. For example, where the integrated circuit has an upper electrochemical material and lower electrochemical material on opposing sides or surfaces of an integrated circuit, the membrane may be an insulative material (or composite material) positioned between the upper and lower electrochemical materials. The outer edge of the membrane may or may not extend beyond the edge of the electrochemical materials, where examples of these differing aspects are reviewed in greater detail below.
As can be seen in the aspect depicted in
Membranes may have “two-dimensional” or “three-dimensional” configurations. Membrane configurations of interest are further described in PCT application serial no. US2008/077753 published as WO2009/042812, as well as U.S. provisional application Ser. Nos. 61/142,849 and 61/173,511; the disclosures of which are herein incorporated by reference. In some instances, IEMs of the invention include a membrane having a configuration that is chosen to provide for reduced susceptibility to signal-compromising events following contact with the target physiological site. One type of signal-compromising event that may occur is where the IEM adheres to a wall of the gastro-intestinal (GI) tract, such as the stomach wall, and thereby is prevented from interacting freely with fluid at the target physiological site. The membrane may be configured in a three-dimensional shape which discourages adhesion to a GI tract wall. One such configuration is shown in
Alternatively, the membrane may include one or more deployable elements which serve to prevent the IEM from adhering to a GI tract wall. An example of such an IEM is shown in
In yet another configuration of interest, the IEM circuitry component is non-centrically positioned relative to the membrane. An example of such an IEM is shown in
Where desired, one or more components which promote movement of the IEM in a liquid environment, such as when present in stomach fluid, may be associated with the membrane. For example, an IEM may have a weight non-centrically associated with a membrane. An example of such a configuration is shown in
To enhance movement of the IEM when present in a liquid environment, such as a target physiological fluid, effervescent structures that generate bubbles upon contact with the target physiological fluid may be associated with one or more locations of the membrane. One or more distinct effervescent structures may be associated with the membrane. Of interest are membranes that include two distinct effervescent structures associated with opposing sides of the membrane, such that a first effervescent structure is present on a first side of the membrane and a second effervescent structure is present on a second side of the membrane. In this orientation, the effervescent structures, upon generation of bubbles, force the IEM to rotate in a liquid environment as a result of opposing forces applied to the edges of the membrane. Representations of IEMs that include effervescent structures are shown in
The membrane may be fabricated from a number of different materials, where the membrane may be made of a single material or be a composite of two or more different types of materials. In choosing a suitable material or materials, one characteristic of interest is mechanical strength. As indicated above, the membrane material may be a composite structure of two or more materials, e.g., an insulative material deposited on a metallic layer.
In certain instances, the membrane will have a mechanical strength sufficient to withstand the mechanical forces typical of the gastrointestinal (GI) tract without folding onto itself and losing its shape. This desired mechanical strength may be chosen to last for at least the duration of the communication, which may be 1 second or longer, such as at least 1 minute or longer, up to 6 hours or longer. In certain aspects, the desired mechanical strength is selected to least for a period of time ranging from 1 to 30 minutes. The desired mechanical strength can be achieved by proper selection of polymer or fillers, or mechanical design (e.g., lamination of multiple layers, or curvature of the amplifier surface) to increase the mechanical strength of the final structure.
Membranes of the invention are ones that are electrically insulating. As such, the materials from which the membranes are fabricated are electrically insulating materials. A given material is electrically insulating if it has a resistivity that is 2 times or greater than the medium in which the device operates (e.g., stomach fluid), such as 10 times or greater, including 100 times or greater than the medium in which the device operates.
Additional characteristics of interest for the membranes include ingestibility and low risk of blockage. It is desirable that the membrane be made of safe and ingestible material, such as food additives or pharmaceutical excipients. It may be further desirable to make the membrane in such a way to ensure low risk for blockage of the GI tract by one or more devices. This can be achieved via chemical or physical dissolution or digestion of the amplifier material, or mechanical breakdown of the membrane, or a combination of the two. For example, the membrane can contain one or more materials that chemically or physically dissolve in GI fluids after a certain amount of time. The material can also be selected to become soluble upon reaching certain parts of the GI tract where the chemical environment is different, for example, a change in pH (e.g., from pH 1-2 in stomach to pH >5 in intestine) or enzymatic components (such as enzymes present in the colon). The membrane may also be mechanically designed to have a weak point that dissolves and allows the entire structure to break up. The membrane may be constituted of several layers, for example an inner soluble or swelling layer and an outer layer that controls the dissolution rate of the inner layer; after a certain amount of time, the inner layer dissolves or swells, bursting apart the entire structure. The membrane does not need to be fully soluble or digestible to eliminate the risk of blockage; it is sufficient that the membrane becomes mechanically pliable or friable enough that it folds or breaks up under modest mechanical strain in the GI tract.
In certain aspects, the membrane may also serve as a reservoir of active pharmaceutical agents. The membrane will then serve the dual purpose of increase the dipole and serving as a drug depot. As summarized above, membranes of interest include an amount of a pharmaceutically active agent. The phrase “pharmaceutically active agent” (also referred to herein as drugs) refers to a compound or mixture of compounds which produces a physiological result, e.g., a beneficial or useful result, upon contact with a living organism, e.g., a mammal, such as a human. Pharmaceutically active agents are distinguishable from such components as excipients, carriers, diluents, lubricants, binders and other formulating aids, and encapsulating or otherwise protective components. The pharmaceutically active agent may be any molecule, as well as binding portion or fragment thereof, that is capable of modulating a biological process in a living subject. In certain aspects, the pharmaceutically active agent may be a substance used in the diagnosis, treatment, or prevention of a disease or as a component of a medication. In certain aspects, the pharmaceutically active agent may be a chemical substance, such as a narcotic or hallucinogen, which affects the central nervous system and causes changes in behavior.
The amount of pharmaceutically active agent that is present in the membrane may vary. In some instances, the amount of pharmaceutically active agent that is present in the membrane may range from 0.01 to 100% by weight. Specific pharmaceutically active agents of interest include, but are not limited to, those described and listed below.
Depending on the particular configuration of a membrane, the disposition of the pharmaceutically active agent in the membrane may vary. For example, the active agent may be homogeneously dispersed in the membrane. Alternatively, the active agent may be confined to a particular location or locations within the membrane, so that the membrane includes regions that have pharmaceutically active agent and regions that do not. An example of such a membrane is a membrane that is porous, where the pores of the membrane are filled with a pharmaceutically active agent. In such aspects, the porosity may range from 5 to 75% or more after swelling.
In some instances, the membrane is configured to provide for controlled release of the pharmaceutically active agent that is present in the membrane. By “controlled release” is meant that the membrane is configured such that the pharmaceutically active agent is released from the membrane upon contact with the target physiological site in a predetermined manner. In other words, pharmaceutically active agent is released from the membrane (upon contact with the target physiological site” in a way that has been predetermined, such as over an extended period of time, etc. As such, the pharmaceutically active agent is released from the membrane at predetermined intervals or gradually over a period of time.
The membrane can be configured to provide for controlled release of the pharmaceutically active agent using a variety of different approaches. For example, where the membrane is a homogenous structure, signal components or ingredients of the membrane may be chosen to provide for controlled release of the pharmaceutically active agent therefrom. Alternatively, where the membrane is porous, the porosity can be chosen to impart the desired controlled release characteristics to the membrane.
In yet other instances, one or more coating layers may be employed to impart controlled release characteristics to the membrane. In some instances, the release profile of the active agent from the membrane is controlled by a single coating applied to the membrane. In yet other aspects, a membrane may include two or more distinct coatings. In yet other instances, the coating layers may be fabricated from partly or entirely soluble polymer matrix materials which provide for a desired controlled release profile. Coatings of interest include those described in greater detail below.
In certain instances, the membrane has a multilayer configuration. Multilayered membrane configurations may be configured in a number of different ways. In some aspects, two or more of the different layers of the multilayered membrane may include the same active agent, where the multilayered configuration (for example where the two different layers have different compositions) provides for a desired controlled release profile of the active agent. In such aspects, the amount of active agent in each active agent comprising layer may be the same or different. In yet other aspects, two or more of the layers of a multilayered membrane may include different active agents.
Where desired, each layer of the multilayered membrane may include an IEM. In such instances, a given IEM will have a multilayered membrane where a distinct IEM is present in two or more layers of the multilayered membrane.
Where desired, the membrane may be configured such that the release of the active agent from the membrane is coupled to the activation of the event marker so that the IEM activation and communication coincides with active agent release, such as the precise start of the release of the active agent from the membrane.
As developed in further detail below, other components of the IEM may be configured to impart a controlled release profile to the active agent associated with the membrane, where these other components may be present instead of or in combination with membrane controlled release components, such as described above. For example, where the IEM includes a vehicle, such as a tablet or capsule, the vehicle may be configured to control release of the active agent from the membrane.
The membrane may be fabricated from various materials, categories of materials, and/or combinations of materials. Material categories of interest include, for example, but are not limited to: matrix materials; filler materials; soluble disintegrant materials; plasticizing agents; coatings; and wetting agents.
The surface of the membrane may also contain an anti-adhesion layer that prevents a transmitter from adhering to the stomach lining or getting blocked by objects in the GI tract such as food residue. An anti-adhesion film may also be used to prevent two or more devices from adhering to each other and blocking each other's communication.
In various aspects, the membrane may be fabricated from various materials, categories of materials, and/or combinations of materials. The categories include, for example, but are not limited to: film forming or binding/adhesive agents; fillers; soluble materials or disintegrants; plasticizing agents; coatings; and wetting agents.
The film forming or binding/adhesive agents include, for example, but are not limited to: agar; carageenan; cellulose acetate; chitosan; copovidone; ethyl cellulose; gelatin; gums (e.g., acacia, xanthan, guar, etc.); sugars (e.g., lactose, mannitol, xylitol, etc.); hydrogels (e.g., hydroxethyl cellulose, sodium alginate, urethane, etc.); acrylic acid polymers, cellulose acetate, hydroxypropylcellulose, hydroxypropylmethylcellulose, hydroxyethylcellulose, carboxymethylcellulose, ethylcellulose, methacrylic acid copolymer, methyl hydroxyethylcellulose, polyethylene glycol, polyvinyl acetate phthalate, polyvinyl alcohol, povidone, starch, carbomers, dextrin, hypromellose, poly(methylvinyl ether/maleic anhydride), chitosan, glyceryl monooleate, polyethylene oxide, polycarbophil, acacia, ceretonia, confectioner's sugar, cottonseed oil, dextrates, dextrose, glyceryl behenate, hydrogenated vegetable oil, hydroxypropyl starch, inulin, lactose, glucose, magnesium aluminum silicate, maltodextrin, maltose, methylcellulose, poloxamer, polycarbophil, polydextrose, polymethacrylates, stearic acid, sucrose, sunflower oil, zein, aluminum stearate, calcium silicate, colloidal silicon dioxide, glyceryl palmitostearate, pectin, polyethylene alkyl ethers, propylene carbonate, sodium ascorbate, zinc acetate, urethane, ammonium alginate, chlorpheniramine maleate, dibutyl phthalate, dibutyl sebacate, diethyl phthalate, dimethyl phthalate, ethyl lactate, vanillin, shellac, and the like.
The fillers include, for example, but are not limited to: oxides, e.g., titanium dioxide, magnesium oxide, etc.; silicates, e.g., magnesium silicate; phosphates, e.g., dicalcium phosphate; carbonates and bicarbonates; starches; cellulosic materials, e.g., microcrystalline cellulose; acacia, agar, alginic acid, carbomers, carboxymethylcellulose, carrageenan, cellulose acetate phthalate, ceratonia, chitosan, confectioner's sugar, copovidone, cottonseed oil, dextrates, dextrin, dextrose, ethylcellulose, gelatin, glyceryl behenate, guar gum, hydrogenated vegetable oil, hydroxyethyl cellulose, hydroxyethylmethyl cellulose, hydroxypropyl cellulose, hydroxypropyl starch, hypromellose, inulin, lactose, glucose, magnesium aluminum silicate, maltodextrin, maltose, methylcellulose, microcrystalline cellulose, poloxamer, polycarbophil, polydextrose, polyethylene oxide, polymethacrylates, povidone, sodium alginate, starch, stearic acid, sucrose, sunflower oil, zein, bentonite, calcium stearate, carbomers, cellulose, colloidal silicon dioxide, kaolin, maltitol, sesame oil, sodium starch glycolate, sorbitan esters, tragacanth, xanthan gum, mannitol, ammonium alginate, calcium carbonate, calcium phosphate, calcium sulfate, cellulose, cellulose acetate, erythritol, fructose, fumaric acid, glyceryl palmitostearate, isomalt, kaolin, lactitol, magnesium carbonate, magnesium oxide, mannitol, simethicone, trehalose, xylitol, and the like.
The soluble materials or disintegrants include, for example, but are not limited to: alginates (e.g., sodium or calcium); crosscarmellose sodium, carbpoxymethyl cellulose sodium, crospovidone, hydroxypropyl, cellulose, hydroxypropyl methyl cellulose, hypromellose, lactose mannitol, polyvinyl alcohol, and salts such as sodium or potassium chloride, alginic acid, calcium alginate, carboxymethylcellulose, cellulose, chitosan, colloidal silicon dioxide, croscarmellose sodium, crospovidone, docusate sodium, guar gum, hydroxypropyl cellulose, magnesium aluminum silicate, methylcellulose, microcrystalline cellulose, polacrilin potassium, povidone, sodium alginate, sodium starch glycolate, starch, and the like.
The plasticizing agents include, for example, but are not limited to dibutyl sebacate, triethyl citrate, andtriacetin, acetyltributyl citrate, acetyltriethyl citrate, benzyl benzoate, cellulose acetate phthalate, chlorbutanol, dextrin, dibutyl phthalate, dibutyl sebacate, diethyl phthalate, dimethyl phthalate, glycerin, glycerin monostearate, hypromellose phthalate, mannitol, mineral oil, lanolin alcohols, palmitic acid, polyethylene glycol, polymethacrylate, polyvinyl acetate phthalate, propylene glycol, 2-pyrolidone, sorbitol, stearic acid, triacetin, tributyl citrate, triethanolamine, triethyl citrate, and the like.
Coatings include, for example, but are not limited to polymethacrylates (pH sensitive) and polyvinyl acetate pthalate (pH sensitive), and hydroxypropyl methylcellulose (moisture barrier), acetyltributyl citrate, acetyltriethyl citrate, calcium carbonate, carboxymethylcellulose sodium, carnauba wax, cellulose acetate, cellulose acetate phthalate, cetyl alcohol, chitosan, ethylcellulose, fructose, gelatin, glycerin, glyceryl behenate, glyceryl palmitostearate, hydroxyethyl cellulose, hydroxyethylmethyl cellulose, hydroxypropyl cellulose, hypromellose, hypromellose phthalate, isomalt, glucose, maltitol, maltodextrin, methylcellulose, microcrystalline wax, paraffin, poloxamer, polydextrose, polyethylene glycol, polyvinyl acetate phthalate, polyvinyl alcohol, povidone, shellac, sucrose, titanium oxide, tributyl citrate, triethyl citrate, vanillin, xylitol, zein, talc, triethanolamine, ammonium alginate, chlorpheniramine maleate, copovidone, ethyl lactate, and the like. When present, coating layers may range in thickness from 0.1 to 200 μm thick, such as 1 to 100 or 1 to 100 μm. Of interest are coating layers that modulate release of the pharmaceutically active agent from the membrane upon contact with a target physiological site.
Wetting agents include, for example, polyethylene glycol, docusate sodium, sodium lauryl sulfate, polyethylene oxide, lecithin, poloxamer, and povidone, benzalkonium chloride, benzethonium chloride, cethylpyridinium chloride, docusate sodium, hypromellose, poloxamer, polythethylene alkyl ethers, polyoxyethylene alkyl ethers, polyoxyethylene castor oil derivatives, polyoxoethylene sorbitan fatty acid esters, polyoxyethylene stearates, sodium lauryl sulfate, sorbitan esters, benzyl alcohol, benzyl benzoate, cetylpyridinium chloride, cyclodextrins, glycerin monostearate, lecithin, meglumine, poloxomer, povidone, sodium bicarbonate, stearic acid, sulfobutylether beta-cyclodextrin, and the like.
The surface of the membrane may also contain an anti-adhesion layer that prevents an IEM from adhering to the stomach lining or getting blocked by objects in the GI tract such as food residue. An anti-adhesion film may also be used to prevent two or more devices from adhering to each other and blocking each other's communication. In these aspects, materials of interest for use in anti-adhesion layers include, but are not limited to: ethyl cellulose, microcrystalline cellulose, cellulose derivative, silicates, e.g., magnesium silicates or aluminum silicates, oxides, e.g., titanium oxide, etc. As indicated above, mixtures of the above materials or materials analogous thereto may be employed.
Of interest in certain aspects are anti-adhesion layers. In these aspects, materials of interest for use in anti-adhesion layers include, but are not limited to: ethyl cellulose, microcrystalline cellulose, cellulose derivative, silicates, e.g., magnesium silicates or aluminum silicates, oxides, e.g., titanium oxide, etc. As indicated above, mixtures of the above materials or materials analogous thereto may be employed.
Membranes may be fabricated using any convenient protocol. Membrane fabrication protocols of interest include, but are not limited to, those described in PCT/US08/77753, the disclosure of which is herein incorporated by reference.
Vehicle
Ingestible event markers may further include a vehicle component with which the IEM and membrane are stably associated. The vehicle component may be any convenient physiologically acceptable carrier composition. By “physiologically acceptable carrier composition” is meant a composition which is ingestible, where the composition may be solid or fluid. Solid vehicle configurations of interest include tablet and capsule configurations. The vehicle component, when present, may be fabricated from a variety of different materials. Materials of interest can be found in Remington's Pharmaceutical Sciences, Mace Publishing Company, Philadelphia, Pa., 17th ed. (1985).
As summarized above, ingestible event markers of the invention may combine one or more IEM/membrane components with a vehicle, where the vehicle may be any convenient physiologically acceptable carrier component. In some instances, the vehicle component is configured to impart a controlled release profile to the pharmaceutically active agent that is associated with the membrane. For example, the IEM/membrane component may be present inside of a solid tablet vehicle, where the solid tablet breaks down after a certain period of time following contact of the IEM with the target physiological site, to allow any active agent present in the IEM to be released.
A vehicle may be present even in those aspects where an active agent is not administered. In some aspects, vehicles are present to enhance ingestibility of an IEM. By stably associating the IEM to a vehicle such as a tablet or capsule (which may be conventionally sized or smaller), adherence of the IEM to the mouth can be avoided. In some instances the vehicle is a small tablet (i.e., mini-tablet) that is adhered to the ingestible event marker, for example with a physiologically acceptable adhesive.
In some instances, IEMs are made up of an IEM stably associated with a solid vehicle component having a tablet configuration. In such instances, of interest are tablet vehicle components that are configured to promote contact of the electrochemical materials or IEM electrochemical materials with fluid upon contact of the IEM with the target physiological site. In such tablet configurations, the tablet may include one or more fluid passageways, such as grooves, channels, tubes or analogous structures, which serve to convey fluid from the environment of the IEM to an electrochemical material associated with a tablet vehicle. Passageway configurations of interest may also be configured to convey any bubbles generated at the electrochemical material component away from the electrochemical material component and/or to discourage formation of bubbles at the electrochemical material component. In such instances, the IEM is configured such that the electrochemical material is positioned relative to the passageway such that fluid in the passageway contacts the electrochemical material. An example of such an IEM is shown in
In these IEM configurations that include one or more fluid passageways, a given fluid passageway may be empty so as to provide uninhibited access of fluid to the electrochemical material component upon contact of the IEM with a fluid. Alternatively, the fluid passageway may be filled with a material that conveys the fluid from the environment to the electrochemical material component, such as material that wicks fluid from one location to another, a hydrogel material that absorbs fluid, and the like. Where desired, salts or other agents which control conductivity may be present.
Pharmaceutically Active Agent
Where desired, the IEM may include a pharmaceutically active agent. As indicated above, the pharmaceutically active agent, when present, may be present in the vehicle and/or membrane. As summarized above, membranes of the invention include an amount of an active agent, such as a pharmaceutically active agent or a diagnostic agent.
“Pharmaceutically Active agent” includes any compound or mixture of compounds which produces a physiological result, e.g., a beneficial or useful result, upon contact with a living organism, e.g., a mammal, such as a human. Pharmaceutically active agents (which may also be referred to herein as “drugs”) are distinguishable from such components as excipients, carriers, diluents, lubricants, binders and other formulating aids, and encapsulating or otherwise protective components. The pharmaceutically active agent may be any molecule, as well as binding portion or fragment thereof, that is capable of modulating a biological process in a living subject. In certain aspects, the pharmaceutically active agent may be a substance used in the diagnosis, treatment, or prevention of a disease or as a component of a medication. In certain aspects, the pharmaceutically active agent may be a chemical substance, such as a narcotic or hallucinogen, which affects the central nervous system and causes changes in behavior.
The pharmaceutically active agent is capable of interacting with a target in a living subject. The target may be a number of different types of naturally occurring structures, where targets of interest include both intracellular and extracellular targets. Such targets may be proteins, phospholipids, nucleic acids and the like, where proteins are of particular interest. Specific proteinaceous targets of interest include, without limitation, enzymes, e.g., kinases, phosphatases, reductases, cyclooxygenases, proteases and the like, targets comprising domains involved in protein-protein interactions, such as the SH2, SH3, PTB and PDZ domains, structural proteins, e.g., actin, tubulin, etc., membrane receptors, immunoglobulins, e.g., IgE, cell adhesion receptors, such as integrins, etc., ion channels, transmembrane pumps, transcription factors, signaling proteins, and the like.
The pharmaceutically active agent may include one or more functional groups necessary for structural interaction with the target, e.g., groups necessary for hydrophobic, hydrophilic, electrostatic or even covalent interactions, depending on the particular drug and its intended target. Where the target is a protein, the pharmaceutically active agent may include functional groups necessary for structural interaction with proteins, such as hydrogen bonding, hydrophobic-hydrophobic interactions, electrostatic interactions, etc., and may include at least an amine, amide, sulfhydryl, carbonyl, hydroxyl or carboxyl group, such as at least two of the functional chemical groups.
Pharmaceutically active agents of interest may include cyclical carbon or heterocyclic structures and/or aromatic or polyaromatic structures substituted with one or more of the above functional groups. Also of interest as pharmaceutically active agents are compounds having structures found among biomolecules, including peptides, saccharides, fatty acids, steroids, purines, pyrimidines, derivatives, structural analogs or combinations thereof. Such compounds may be screened to identify those of interest, where a variety of different screening protocols are known in the art.
The pharmaceutically active agent may be derived from a naturally occurring or synthetic compound that may be obtained from a wide variety of sources, including libraries of synthetic or natural compounds. For example, numerous means are available for random and directed synthesis of a wide variety of organic compounds and biomolecules, including the preparation of randomized oligonucleotides and oligopeptides. Alternatively, libraries of natural compounds in the form of bacterial, fungal, plant and animal extracts are available or readily produced. Additionally, natural or synthetically produced libraries and compounds are readily modified through conventional chemical, physical and biochemical means, and may be used to produce combinatorial libraries. Known pharmacological agents may be subjected to directed or random chemical modifications, such as acylation, alkylation, esterification, amidification, etc. to produce structural analogs.
As such, the pharmaceutically active agent may be obtained from a library of naturally occurring or synthetic molecules, including a library of compounds produced through combinatorial means, i.e., a compound diversity combinatorial library. When obtained from such libraries, the drug moiety employed will have demonstrated some desirable activity in an appropriate screening assay for the activity. Combinatorial libraries, as well as methods for producing and screening such libraries, are known in the art and described in U.S. Pat. Nos. 5,741,713; 5,734,018; 5,731,423; 5,721,099; 5,708,153; 5,698,673; 5,688,997; 5,688,696; 5,684,711; 5,641,862; 5,639,603; 5,593,853; 5,574,656; 5,571,698; 5,565,324; 5,549,974; 5,545,568; 5,541,061; 5,525,735; 5,463,564; 5,440,016; 5,438,119; 5,223,409, the disclosures of which are herein incorporated by reference.
Broad categories of active agents of interest include, but are not limited to: cardiovascular agents; pain-relief agents, e.g., analgesics, anesthetics, anti-inflammatory agents, etc.; nerve-acting agents; chemotherapeutic (e.g., anti-neoplastic) agents; neurological agents, e.g., anti-convulsants, etc.
Pharmaceutically active agents of interest include, but are not limited to: those listed in PCT application serial no. PCT/US2006/016370, the disclosure of which listed pharmaceutically active agents is incorporated herein by reference.
Salt
Where desired, a given IEM may include a non-active agent salt component, which component is made up of one or more non-active agent salts. In some instances, the amount of this salt component present in the IEM is chosen to be sufficient to enhance the strength of the communication generated by the IEM of the IEM when the IEM contacts the target physiological site, such as the stomach. The magnitude of communication strength enhancement may vary, where in some instances the magnitude of communication strength enhancement is 10× or more, such as 20× or more, including 50× or more, as compared to a suitable control (such as the strength of a communication generated by an analogous IEM which differs from the test IEM of interest solely by lack of the salt component). The amount of this non-active agent salt component is sufficient to provide for the desired communication strength enhancement. Non-active agent salts may vary, where non-active agent salts of interest include, but are not limited to: salts of physiologically acceptable electrolytes, such as but not limited to: sodium ion, chloride ion, potassium ion and calcium ion, magnesium ion, etc. Specific physiologically compatible salts of interest include, but are not limited to: KCl, NaCl, MgCl2, and the like. When present, this non-active agent salt may be part of one or more of: the membrane, the IEM and the vehicle.
Anti-Foaming Agent
Also of interest are anti-foaming agents, which agents decrease the surface tension of gas bubbles. Anti-foaming agents of interest include, but are not limited to: silicone oil-based agents, such as simethicone, sorbitan sesquoleate, etc. When present, the amount of anti-foaming agent present in the IEM may vary, ranging from 0.01 to 10 mg, such as 0.1 to 100 μg, and including 0.1 to 10 μg. When present, this anti-foaming agent may be part of one or more of: the membrane, the IEM and the vehicle.
Surfactants
In some instances, the IEM includes one or more surfactants. Surfactants of interest include, but are not limited to: ionic surfactants, such as anionic surfactants, cationic surfactants and zwitterionic surfactants, as well as nonionic surfactants and surface active biological modifiers. Surfactants of interest include, but are not limited to: castor oil derivatives, cholesterol, polyglycolyzed glycerides, acetylated monoglycerides, sorbitan fatty acid esters, poloxamers, polysorbates, polyoxyethylene sorbitan fatty acid esters, polyoxyethylene compounds, monoglycerides or ethoxylated derivatives thereof, diglycerides or polyoxyethylene derivatives thereof, sodium docusate, sodium laurylsulfate, cholic acid or derivatives thereof, ethoxylated alcohols, ethoxylated esters, ethoxylated amides, polyoxypropylene compounds, propoxylated alcohols, ethoxylated/propoxylated block polymers, propoxylated esters, alkanolamides, amine oxides, fatty acid esters of polyhydric alcohols, ethylene glycol esters, diethylene glycol esters, propylene glycol esters, glycerol esters, polyglycerol fatty acid esters, SPAN™ surfactants, such as sorbitan esters), TWEEN™ surfactants, such as sucrose esters, glucose (dextrose) esters, alkali metal sulfates, quaternary ammonium compounds, amidoamines, and aminimides, simethicone, lecithins, alcohols, phospholipids, and mixtures thereof. When present, the surfactant component may be 0.01 to 10%, such as 0.01 to 100 ppm, including 0.1 to 100 ppm of the IEM composition. When present, surfactants may be part of one or more of: the membrane, the IEM and the vehicle.
Disintegrants
In some instances, the IEM compositions include one or more disintegrants. By disintegrant is meant an agent that enhances break up of at least some portion of the IEM, such as the vehicle or membrane, upon contact with the target physiological site. As such, disintegrants may facilitate mechanical disruption of the IEM vehicle component, such as a tablet, when the IEM contacts a fluid, such as stomach fluid. Disintegrants of interest include, but are not limited to, those disintegrants listed above, such as microcrystalline cellulose, starch, sodium starch glycolate, crosslinked polyvinylpyrrolidone, crosslinked carboxymethylcellulose, alginic acid, etc. When present, the disintegrant component may range from about 0.01 to 15%, such as 0.01 to 100 ppm, including 0.1 to 10 ppm of the IEM composition. When present, disintegrants may be part of one or more of: the membrane, the IEM and the vehicle.
Antioxidants
The IEM compositions may also include one or more antioxidants which serve to enhance shelf-life stability of the IEM. Antioxidants of interest include, but are not limited to: tocopherol and derivatives, ascorbic acid and derivatives, butylated hydroxyanisole, butylated hydroxytoluene, fumaric acid, malic acid, propyl gallate, metabisulfates and derivatives. When present, antioxidants may range from 0.01 to 10%, such as 0.01 to 100 ppm and including 0.1 to 1 ppm. When present, anti-oxidants may be part of one or more of: the membrane, the IEM and the vehicle.
Preservatives
IEMs of the invention may further include preservatives such as, but not limited to, benzalkonium chloride and derivatives, benzoic acid, benzyl alcohol and derivatives, bronopol, parabens, centrimide, chlorhexidine, cresol and derivatives, imidurea, phenol, phenoxyethanol, phenylethyl alcohol, phenylmercuric salts, thimerosal, sorbic acid and derivatives. The preservative may be present from in amounts ranging from 0.01 to 10 mg, such as 0.1 to 100 μg and including 0.1 to 1 μg. When present, preservatives may be part of one or more of: the membrane, the IEM and the vehicle.
Micro-Environment Modification Agents
IEMs of the invention may include one or more micro-environment modification agents that modify or control the micro-environment of an IEM upon contact with a target physiological site. Micro-environment modification agents of interest include but are not limited to surfactants, distintegrants, anti-oxidants, and preservatives. A given IEM may include one or more of these components as a micro-environment modification agent. Examples and amounts of each of these types of agents that may be present are provided above. When present, micro-environment modification agents may be part of one or more of: the membrane, the IEM and the vehicle.
Balanced Soluble/Insoluble Components
In some instances, IEM compositions of the invention are those in which the water insoluble and water soluble components of the vehicle are present in a ratio that is selected to provide for desired characteristics, such as dissolution of the vehicle, operations of the IEM, and the like. In some instances, the fraction of water insoluble components in the vehicle may range from 0.01 to 1, such as 0.1 to 0.9 and including 0.5 to 0.8. In some instances, the ingestible event marker has a fraction of soluble components up to 90% by weight.
Absorbent Component
An ingestible event marker may include a component that absorbs fluid, e.g., water, in order to increase the weight of the IEM (for example to ensure that the IEM sinks when it contacts fluid at a physiological site). This absorbent component may be the membrane, vehicle, or some distinct component of the IEM, such as an overlayer or coating, as desired. When present, this absorbent component may be fabricated from a variety of suitable materials, such as the hydrogel materials listed above.
Controlled Activation Element
IEMs of the invention may include a controlled activation element. The controlled activation element of the IEM that provides for controlled activation may be responsive to a variety of different types of stimuli. Stimuli of interest for which the controlled activation element can be configured to be responsive to include but are not limited to: liquid (wetting), time, pH, ionic strength, conductivity, biological molecules (e.g. specific proteins or enzymes that are present in the stomach, small intestine, colon), blood, temperature, specific auxiliary agents (foods ingredients such as fat, salt, or sugar, or other pharmaceuticals whose co-presence is clinically relevant), bacteria in the stomach, pressure, and light.
The controlled activation element is made up of one or more components that provides for the desired controlled activation functionality, such that the controlled activation element is responsive to the stimulus of interest. The nature of the component or components that make up the controlled activation element may vary. For example, where the stimulus of interest is temperature, the controlled activation element may be a barrier of a material, such as a film (e.g., a polymeric film) whose solubility is a function of temperature, specifically one that becomes soluble at or near body temperature. Such a film may be insoluble/impermeable to water at room temperature but soluble/permeable at 37° C. Materials of interest that may be used for such films include, but are not limited to the polymeric materials listed below. In those aspects where pressure is the stimuli of interest, the controlled activation element may be a pressure sensitive material, e.g., a capsule or shell (for example, made of a cellulosic material), that has a specific mechanical strength such that at a pressure threshold above the threshold the element will be crushed and allow the highly reliable event marker to be activated and communicate. In other aspects of interest, the stimulus may be light. For example, the stimulus may be a fluorescent label which has been attached to a tumor. As the IEM passes by the tumor, the controlled activation element may include a component that provides light at a stimulating wavelength for the label and also a component that detects emitted light from the label. Any convenient light source and detector may be employed. When the detector component detects the emitted light, it will activate the IEM in a controlled activation manner.
In certain aspects, the one or more controlled activation components of the invention provide for controlled activation, i.e., activation in a manner that is substantially, if not completely, independent of target site environment, as reviewed above. In one aspect of interest, the controlled activation component includes a dried conductive medium that, upon combination with target site fluid, produces an ionic medium in the presence of the first and second dissimilar materials to activate the battery, e.g., as reviewed above. When present, the dried conductive medium precursor may be any of a variety of different types of compositions. Compositions of interest include, but are not limited to: salts of physiologically acceptable electrolytes, such as but not limited to: sodium ion, chloride ion, potassium ion and calcium ion, magnesium ion, etc. Specific physiologically compatible salts of interest include, but are not limited to: KCl, NaCl, MgCl2, and the like. Aspects of the invention include the presence of a dried conductive medium precursor. When the precursor is a salt, e.g., as described above, the dried salt may be provided in any convenient format, such as a lyophilized salt composition.
Controlled activation elements of interest are further described in PCT application serial no. PCT/US2007/082563 published as WO 2008/052136; the disclosure of which is herein incorporated by reference.
IEM Manufacture
A variety of manufacturing protocols may be employed to produce IEMs of the invention. Where the IEM does not include a vehicle, the IEM and membrane components may be produced as described above. Where the IEM further includes a vehicle, the IEM may be stably associated with the vehicle in some manner. By stably associated is meant that the IEM and the vehicle do not separate from each other, at least until administered to the subject in need thereof, e.g., by ingestion. The IEM may be stably associated with the vehicle in a number of different ways.
IEM fabrication protocols of interest include, but are not limited to, those described in PCT application serial nos. PCT/US2006/016370 and PCT/US08/77753; as well as in U.S. Provisional Application Ser. No. 61/142,849; the disclosures of which are herein incorporated by reference.
Systems
Also provided are systems that include an IEM and a communication detection component, e.g., in the form of a receiver, sometimes referred to herein as a “detector”. Receivers of interest are those that are configured to receive a signal from an IEM. The detection component may vary significantly depending on the nature of the communication that is generated by the IEM. As such, the receiver may be configured to receive a variety of different types of communications, including but not limited to: RF signals, magnetic signals, conductive (near field) signals, acoustic signals, etc. In certain aspects, the receiver is configured to receive a signal conductively from an IEM, such that the two components use the body of the patient as a communication medium. As such, the signal that is transferred between the IEM and the receiver travels through the body, and requires the body as the conduction medium. The IEM emitted signal may be transmitted through and received from the skin and other body tissues of the subject body in the form of electrical alternating current (a.c.) voltage signals that are conducted through the body tissues. As a result, such aspects do not require any additional cable or hard wire connection, or even a radio link connection for transmitting the sensor data from the autonomous sensor units to the central transmitting and receiving unit and other components of the system, since the sensor data are directly exchanged via the skin and other body tissues of the subject. This communication protocol has the advantage that the receivers may be adaptably arranged at any desired location on the body of the subject, whereby the receivers are automatically connected to the required electrical conductor for achieving the communication, i.e., the communication is carried out through the electrical conductor provided by the skin and other body tissues of the subject.
The receiver may include a variety of different types of receiver elements, where the nature of the receiver element necessarily varies depending on the nature of the signal produced by the signal generation element. In certain aspects, the receiver may include one or more electrochemical materials (such as 2 or more electrochemical materials, 3 or more electrochemical materials, and/or includes multiple pairs of electrochemical materials, such as 2 or more, 3 or more, 4 or more pairs of electrochemical materials, etc., for detecting signal emitted by an IEM. In certain aspects, the receiver includes two or three electrochemical materials that are dispersed at a distance from each other, e.g., a distance that allows the electrochemical materials to detect a differential voltage. The distance between any two electrochemical materials may vary, and in certain aspects ranges from about 0.1 to about 5 cm, such as from about 0.5 to about 2.5 cm, e.g., about 1 cm.
In addition to receiving elements, such as electrodes electrochemical materials, receivers of the invention may include one or more integrated circuit components, one or more power components (such as power receivers or batteries), signal transmission components, housing components, etc.
The receivers of interest include both external and implantable receivers. In external aspects, the receiver is ex vivo, by which is meant that the receiver is present outside of the body during use. Where the receiver is implanted, the receiver is in vivo. The receiver is configured to be stably associated with the body, e.g., either in vivo or ex vivo, at least during the time that it receives the emitted signal from the IEM.
In certain aspects, the receiver is configured to provide data of a received signal to a location external to said subject. For example, the receiver may be configured to provide data to an external data receiver, e.g., which may be in the form of a monitor (such as a bedside monitor), a computer, a personal digital assistant (PDA), phone, messaging device, smart phone, etc. The receiver may be configured to retransmit data of a received signal to the location external to said subject. Alternatively, the receiver may be configured to be interrogated by an external interrogation device to provide data of a received signal to an external location.
Receivers of interest include, but are not limited to, those receivers disclosed in: PCT application serial nos. PCT/US2006/016370 published as WO 2006/116718; PCT/US2008/52845 published as WO 2008/095183; PCT/US2007/024225 published as WO 2008/063626 and PCT/US2008/085048; as well as U.S. Provisional Application Ser. No. 61/160,289; the disclosures of which applications (and particularly receiver components thereof) are herein incorporated by reference.
Systems of the invention may include an external device which is distinct from the receiver (which may be implanted or topically applied in certain aspects), where this external device provides a number of functionalities. Such an apparatus can include the capacity to provide feedback and appropriate clinical regulation to the patient. Such a device can take any of a number of forms. By example, the device can be configured to sit on the bed next to the patient, e.g., a bedside monitor. Other formats include, but are not limited to, PDAs, phones, such as smart phones, computers, etc. In some instances, the external device is configured to provide pharmacologic and physiologic information in a form that can be transmitted through a transmission medium, such as a telephone line, to a remote location such as a clinician or to a central monitoring agency. The external device can read out the information described in more detail in other sections of the subject patent application, both from pharmaceutical ingestion reporting and from physiological sensing devices, such as is produced internally by a pacemaker device or a dedicated implant for detection of the pill. The purpose of the external apparatus is to get the data out of the patient and into an external device. One feature of the external apparatus is its ability to provide pharmacologic and physiologic information in a form that can be transmitted through a transmission medium, such as a telephone line, to a remote location such as a clinician or to a central monitoring agency.
Methods
Aspects of the invention further include methods of using IEMs, such as those described above. Methods of the invention generally include administering an IEM to a subject, e.g., by self-administration or via the assistance of another, such as a health care practitioner. Generally, methods of the invention will include placing the IEM in the mouth of a subject such that the subject swallows the IEM. In this manner, the subject ingests the IEM. IEMs may be employed with a variety of subjects. Generally such subjects are “mammals” or “mammalian,” where these terms are used broadly to describe organisms which are within the class mammalia, including the orders carnivore (e.g., dogs and cats), rodentia (e.g., mice, guinea pigs, and rats), and primates (e.g., humans, chimpanzees, and monkeys). In certain aspects, the subjects will be humans.
Following ingestion, the methods include emitting one or more signals from the ingested IEM, for example when the IEM contacts the target physiological site. As reviewed above, the nature of the emitted signal may vary greatly. In some instances, the emitted signal is a conductively transmitted signal. Methods of the invention may also include receiving a signal emitted from an IEM, e.g., at a receiver, such as described above. In some instances, the received signal is a conductively transmitted signal.
IEMs may be employed in a variety of different applications, which applications may be both medical and non-medical in nature. Applications of interest include, but are not limited to: monitoring patient compliance with prescribed therapeutic regimens; tailoring therapeutic regimens based on patient compliance; monitoring patient compliance in clinical trials; monitoring usage of controlled substances; monitoring the occurrence of a personal event of interest, such as the onset of symptoms, etc., and the like. Applications of interest are further described in PCT application serial no. PCT/US2006/016370 published as WO/2006/116718; PCT application serial no. PCT/US2007/082563 published as WO/2008/052136; PCT application serial no. PCT/US2007/024225 published as WO/2008/063626; PCT application serial no. PCT/US2007/022257 published as WO/2008/066617; PCT application serial no. PCT/US2008/052845 published as WO/2008/095183; PCT application serial no. PCT/US2008/053999 published as WO/2008/101107; PCT application serial no. PCT/US2008/056296 published as WO/2008/112577; PCT application serial no. PCT/US2008/056299 published as WO/2008/112578; and PCT application serial no. PCT/US2008/077753; the disclosures of which are herein incorporated by reference.
Kits
Also provided are kits that include one or more IEMs, such as described above. In those aspects having a plurality of IEMs, the IEMs may be packaged in a single container, e.g., a single tube, bottle, vial, and the like, or one or more dosage amounts may be individually packaged such that certain kits may have more than one container of IEMs. In certain aspects the kits may also include a receiver, such as reviewed above. In certain aspects, the kits may also include an external monitor device, e.g., as described above, which may provide for communication with a remote location, e.g., a doctor's office, a central facility etc., which obtains and processes data obtained about the usage of the composition.
The subject kits may also include instructions for how to practice the subject methods using the components of the kit. The instructions may be recorded on a suitable recording medium or substrate. For example, the instructions may be printed on a substrate, such as paper or plastic, etc. As such, the instructions may be present in the kits as a package insert, in the labeling of the container of the kit or components thereof (i.e., associated with the packaging or sub-packaging) etc. In other aspects, the instructions are present as an electronic storage data file present on a suitable computer readable storage medium, e.g. CD-ROM, diskette, etc. In yet other aspects, the actual instructions are not present in the kit, but means for obtaining the instructions from a remote source, e.g. via the internet, are provided. An example of this aspect is a kit that includes a web address where the instructions can be viewed and/or from which the instructions can be downloaded. As with the instructions, this means for obtaining the instructions is recorded on a suitable substrate.
Some or all components of the subject kits may be packaged in suitable packaging to maintain sterility. In many aspects of the subject kits, the components of the kit are packaged in a kit containment element to make a single, easily handled unit, where the kit containment element, e.g., box or analogous structure, may or may not be an airtight container, e.g., to further preserve the sterility of some or all of the components of the kit.
It is to be understood that this invention is not limited to particular aspects described, as such may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular aspects only, and is not intended to be limiting, since the scope of the present invention will be limited only by the appended claims.
Where a range of values is provided, it is understood that each intervening value, to the tenth of the unit of the lower limit unless the context clearly dictates otherwise, between the upper and lower limit of that range and any other stated or intervening value in that stated range, is encompassed within the invention. The upper and lower limits of these smaller ranges may independently be included in the smaller ranges and are also encompassed within the invention, subject to any specifically excluded limit in the stated range. Where the stated range includes one or both of the limits, ranges excluding either or both of those included limits are also included in the invention.
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any methods and materials similar or equivalent to those described herein can also be used in the practice or testing of the present invention, representative illustrative methods and materials are now described.
All publications and patents cited in this specification are herein incorporated by reference as if each individual publication or patent were specifically and individually indicated to be incorporated by reference and are incorporated herein by reference to disclose and describe the methods and/or materials in connection with which the publications are cited. The citation of any publication is for its disclosure prior to the filing date and should not be construed as an admission that the present invention is not entitled to antedate such publication by virtue of prior invention. Further, the dates of publication provided may be different from the actual publication dates which may need to be independently confirmed.
It is noted that, as used herein and in the appended claims, the singular forms “a”, “an”, and “the” include plural referents unless the context clearly dictates otherwise. It is further noted that the claims may be drafted to exclude any optional element. As such, this statement is intended to serve as antecedent basis for use of such exclusive terminology as “solely,” “only” and the like in connection with the recitation of claim elements, or use of a “negative” limitation.
As will be apparent to those of skill in the art upon reading this disclosure, each of the individual aspects described and illustrated herein has discrete components and features which may be readily separated from or combined with the features of any of the other several aspects without departing from the scope or spirit of the present invention. Any recited method can be carried out in the order of events recited or in any other order which is logically possible.
Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it is readily apparent to those of ordinary skill in the art in light of the teachings of this invention that certain changes and modifications may be made thereto without departing from the spirit or scope of the appended claims.
Accordingly, the preceding merely illustrates the principles of the invention. It will be appreciated that those skilled in the art will be able to devise various arrangements which, although not explicitly described or shown herein, embody the principles of the invention and are included within its spirit and scope. Furthermore, all examples and conditional language recited herein are principally intended to aid the reader in understanding the principles of the invention and the concepts contributed by the inventors to furthering the art, and are to be construed as being without limitation to such specifically recited examples and conditions. Moreover, all statements herein reciting principles, aspects, and aspects of the invention as well as specific examples thereof, are intended to encompass both structural and functional equivalents thereof. Additionally, it is intended that such equivalents include both currently known equivalents and equivalents developed in the future, i.e., any elements developed that perform the same function, regardless of structure. The scope of the present invention, therefore, is not intended to be limited to the exemplary aspects shown and described herein. Rather, the scope and spirit of present invention is embodied by the appended claims.
This application is a continuation of U.S. patent application Ser. No. 13/756,280, filed on Jan. 31, 2013, entitled “HIGHLY RELIABLE INGESTIBLE EVENT MARKERS AND METHODS FOR USING THE SAME”, now U.S. Pat. No. 9,320,455, which application is a continuation of U.S. patent application Ser. No. 12/744,642, filed on May 25, 2010, entitled “HIGHLY RELIABLE INGESTIBLE EVENT MARKERS AND METHODS FOR USING THE SAME” now U.S. Pat. No. 8,545,402, which application is a 371 application of International Application No. PCT/US2010/032590, filed on Apr. 27, 2010, and which application, pursuant to 35 U.S.C. § 119 (e), claims priority to the filing date of U.S. Provisional Patent Application Ser. No. 61/173,511 filed Apr. 28, 2009 and to the filing date of U.S. Provisional Patent Application Ser. No. 61/173,564 filed Apr. 28, 2009; the disclosure of which applications are herein incorporated by reference.
| Number | Name | Date | Kind |
|---|---|---|---|
| 1548459 | Hammer | Aug 1925 | A |
| 2587158 | Hofberg | Feb 1952 | A |
| 2973555 | Schwepke | Mar 1961 | A |
| 3048526 | Boswell | Aug 1962 | A |
| 3079824 | Schott | Mar 1963 | A |
| 3096248 | Rudzki | Jul 1963 | A |
| 3176399 | Marino et al. | Apr 1965 | A |
| 3589943 | Grubb et al. | Jun 1971 | A |
| 3607788 | Adolph | Sep 1971 | A |
| 3642008 | Bolduc | Feb 1972 | A |
| 3679480 | Brown et al. | Jul 1972 | A |
| 3682160 | Murata | Aug 1972 | A |
| 3719183 | Schwartz | Mar 1973 | A |
| 3799802 | Schneble, Jr. et al. | Mar 1974 | A |
| 3828766 | Krasnow | Aug 1974 | A |
| 3837339 | Aisenberg et al. | Sep 1974 | A |
| 3849041 | Knapp | Nov 1974 | A |
| 3893111 | Cotter | Jul 1975 | A |
| 3944064 | Bashaw et al. | Mar 1976 | A |
| 3967202 | Batz | Jun 1976 | A |
| 3989050 | Buchalter | Nov 1976 | A |
| 4017856 | Wiegand | Apr 1977 | A |
| 4055178 | Harrigan | Oct 1977 | A |
| 4062750 | Butler | Dec 1977 | A |
| 4077397 | Ellis | Mar 1978 | A |
| 4077398 | Ellis | Mar 1978 | A |
| 4082087 | Howson | Apr 1978 | A |
| 4090752 | Long | May 1978 | A |
| 4106348 | Auphan | Aug 1978 | A |
| 4129125 | Lester | Dec 1978 | A |
| 4139589 | Beringer et al. | Feb 1979 | A |
| 4143770 | Grimmell et al. | Mar 1979 | A |
| 4166453 | McClelland | Sep 1979 | A |
| 4239046 | Ong | Dec 1980 | A |
| 4251795 | Shibasaki et al. | Feb 1981 | A |
| 4269189 | Abraham | May 1981 | A |
| 4331654 | Morris | May 1982 | A |
| 4345588 | Widder et al. | Aug 1982 | A |
| 4418697 | Tama | Dec 1983 | A |
| 4425117 | Hugemann | Jan 1984 | A |
| 4439196 | Higuchi | Mar 1984 | A |
| 4494950 | Fischell | Jan 1985 | A |
| 4559950 | Vaughan | Dec 1985 | A |
| 4564363 | Bagnall et al. | Jan 1986 | A |
| 4635641 | Hoffman | Jan 1987 | A |
| 4654165 | Eisenber | Mar 1987 | A |
| 4663250 | Ong et al. | May 1987 | A |
| 4669479 | Dunseath | Jun 1987 | A |
| 4687660 | Baker et al. | Aug 1987 | A |
| 4725997 | Urquhart et al. | Feb 1988 | A |
| 4749575 | Rotman et al. | Jun 1988 | A |
| 4763659 | Dunseath | Aug 1988 | A |
| 4767627 | Caldwell et al. | Aug 1988 | A |
| 4775536 | Patell | Oct 1988 | A |
| 4784162 | Ricks | Nov 1988 | A |
| 4793825 | Benjamin et al. | Dec 1988 | A |
| 4814181 | Jordan et al. | Mar 1989 | A |
| 4844076 | Lesho | Jul 1989 | A |
| 4847090 | Della Posta et al. | Jul 1989 | A |
| 4876093 | Theeuwes et al. | Oct 1989 | A |
| 4891223 | Ambegaonkar | Jan 1990 | A |
| 4896261 | Nolan | Jan 1990 | A |
| 4900552 | Sanvordeker et al. | Feb 1990 | A |
| 4975230 | Pinkhasov | Dec 1990 | A |
| 4987897 | Funke | Jan 1991 | A |
| 5000957 | Eckenhoff et al. | Mar 1991 | A |
| 5016634 | Vock et al. | May 1991 | A |
| 5018335 | Yamamoto et al. | May 1991 | A |
| 5079006 | Urguhart | Jan 1992 | A |
| 5110441 | Kinlen et al. | May 1992 | A |
| 5160885 | Hannam et al. | Nov 1992 | A |
| 5167626 | Casper | Dec 1992 | A |
| 5176626 | Soehendra | Jan 1993 | A |
| 5187723 | Mueller | Feb 1993 | A |
| 5213738 | Hampton et al. | May 1993 | A |
| 5218343 | Stobbe et al. | Jun 1993 | A |
| 5261402 | DiSabito | Nov 1993 | A |
| 5263481 | Axelgaard et al. | Nov 1993 | A |
| 5273066 | Graham et al. | Dec 1993 | A |
| 5279607 | Schentag et al. | Jan 1994 | A |
| 5281287 | Lloyd | Jan 1994 | A |
| 5283136 | Peled et al. | Feb 1994 | A |
| 5288564 | Klein | Feb 1994 | A |
| 5305745 | Zacouto | Apr 1994 | A |
| 5310301 | Aono | May 1994 | A |
| 5318557 | Gross | Jun 1994 | A |
| 5331953 | Andersson et al. | Jul 1994 | A |
| 5394882 | Mawhinney | Mar 1995 | A |
| 5395366 | D'Andrea et al. | Mar 1995 | A |
| 5436091 | Shackle et al. | Jul 1995 | A |
| 5443461 | Atkinson et al. | Aug 1995 | A |
| 5443843 | Curatolo et al. | Aug 1995 | A |
| 5458141 | Neil et al. | Oct 1995 | A |
| 5458994 | Nesselbeck et al. | Oct 1995 | A |
| 5485841 | Watkin et al. | Jan 1996 | A |
| 5506248 | Nikfar et al. | Apr 1996 | A |
| 5551020 | Flax et al. | Aug 1996 | A |
| 5567210 | Bates et al. | Oct 1996 | A |
| 5596302 | Mastrocola et al. | Jan 1997 | A |
| 5600548 | Nguyen et al. | Feb 1997 | A |
| 5603363 | Nelson | Feb 1997 | A |
| 5634468 | Platt | Jun 1997 | A |
| 5645063 | Straka et al. | Jul 1997 | A |
| 5659247 | Clements | Aug 1997 | A |
| 5703463 | Smith | Dec 1997 | A |
| 5705189 | Lehmann et al. | Jan 1998 | A |
| 5724432 | Bouvet et al. | Mar 1998 | A |
| 5738708 | Peachey et al. | Apr 1998 | A |
| 5740811 | Hedberg | Apr 1998 | A |
| 5757326 | Koyama et al. | May 1998 | A |
| 5772575 | Lesinski et al. | Jun 1998 | A |
| 5792048 | Schaefer | Aug 1998 | A |
| 5802467 | Salazar | Sep 1998 | A |
| 5833716 | Bar-Or | Nov 1998 | A |
| 5842324 | Grosskopf et al. | Dec 1998 | A |
| 5845265 | Woolston | Dec 1998 | A |
| 5862803 | Besson | Jan 1999 | A |
| 5868136 | Fox | Feb 1999 | A |
| 5914132 | Kelm et al. | Jun 1999 | A |
| 5914701 | Gersheneld et al. | Jun 1999 | A |
| 5925030 | Gross et al. | Jul 1999 | A |
| 5957854 | Besson et al. | Sep 1999 | A |
| 5963132 | Yoakum et al. | Oct 1999 | A |
| 5974124 | Schlueter, Jr. et al. | Oct 1999 | A |
| 5981166 | Mandecki | Nov 1999 | A |
| 5999846 | Pardey et al. | Dec 1999 | A |
| 6018229 | Mitchell et al. | Jan 2000 | A |
| 6038464 | Axelgaard et al. | Mar 2000 | A |
| 6042710 | Dubrow | Mar 2000 | A |
| 6047203 | Sackner | Apr 2000 | A |
| 6068465 | Wilson | May 2000 | A |
| 6068589 | Neukermans | May 2000 | A |
| 6076016 | Feierbach et al. | Jun 2000 | A |
| 6081734 | Batz | Jun 2000 | A |
| 6091975 | Daddona et al. | Jul 2000 | A |
| 6095985 | Raymond et al. | Aug 2000 | A |
| 6115636 | Ryan | Sep 2000 | A |
| 6122351 | Schlueter, Jr. et al. | Sep 2000 | A |
| 6141592 | Pauly | Oct 2000 | A |
| 6149940 | Maggi et al. | Nov 2000 | A |
| 6200265 | Walsh et al. | Mar 2001 | B1 |
| 6206702 | Hayden et al. | Mar 2001 | B1 |
| 6217744 | Crosby | Apr 2001 | B1 |
| 6231593 | Meserol | May 2001 | B1 |
| 6245057 | Sieben et al. | Jun 2001 | B1 |
| 6269058 | Yamanoi et al. | Jul 2001 | B1 |
| 6285897 | Kilcoyne et al. | Sep 2001 | B1 |
| 6287252 | Lugo | Sep 2001 | B1 |
| 6288629 | Cofino et al. | Sep 2001 | B1 |
| 6289238 | Besson et al. | Sep 2001 | B1 |
| 6315719 | Rode et al. | Nov 2001 | B1 |
| 6317714 | Del Castillo | Nov 2001 | B1 |
| 6342774 | Kreisinger et al. | Jan 2002 | B1 |
| 6344824 | Takasugi et al. | Feb 2002 | B1 |
| 6358202 | Arent | Mar 2002 | B1 |
| 6364834 | Reuss | Apr 2002 | B1 |
| 6366206 | Ishikawa et al. | Apr 2002 | B1 |
| 6371927 | Brune | Apr 2002 | B1 |
| 6374670 | Spelman | Apr 2002 | B1 |
| 6380858 | Yarin et al. | Apr 2002 | B1 |
| 6390088 | Noehl et al. | May 2002 | B1 |
| 6394997 | Lemelson | May 2002 | B1 |
| 6426863 | Munshi | Jul 2002 | B1 |
| 6432292 | Pinto et al. | Aug 2002 | B1 |
| 6440069 | Raymond et al. | Aug 2002 | B1 |
| 6441747 | Khair | Aug 2002 | B1 |
| 6453199 | Kobozev | Sep 2002 | B1 |
| 6477424 | Thompson et al. | Nov 2002 | B1 |
| 6496705 | Ng et al. | Dec 2002 | B1 |
| 6526315 | Inagawa | Feb 2003 | B1 |
| 6531026 | Takeichi et al. | Mar 2003 | B1 |
| 6544174 | West | Apr 2003 | B2 |
| 6547994 | Monkhouse et al. | Apr 2003 | B1 |
| 6564079 | Cory | May 2003 | B1 |
| 6567685 | Takamori et al. | May 2003 | B2 |
| 6572636 | Hagen et al. | Jun 2003 | B1 |
| 6577893 | Besson et al. | Jun 2003 | B1 |
| 6579231 | Phipps | Jun 2003 | B1 |
| 6595929 | Stivoric | Jul 2003 | B2 |
| 6599284 | Faour et al. | Jul 2003 | B2 |
| 6602518 | Seielstad et al. | Aug 2003 | B2 |
| 6605038 | Teller | Aug 2003 | B1 |
| 6609018 | Cory | Aug 2003 | B2 |
| 6612984 | Kerr | Sep 2003 | B1 |
| 6632175 | Marshall | Oct 2003 | B1 |
| 6632216 | Houzego | Oct 2003 | B2 |
| 6635279 | Kolter et al. | Oct 2003 | B2 |
| 6643541 | Mok et al. | Nov 2003 | B2 |
| 6654638 | Sweeney | Nov 2003 | B1 |
| 6663846 | McCombs | Dec 2003 | B1 |
| 6673474 | Yamamoto | Jan 2004 | B2 |
| 6680923 | Leon | Jan 2004 | B1 |
| 6689117 | Sweeney et al. | Feb 2004 | B2 |
| 6694161 | Mehrotra | Feb 2004 | B2 |
| 6704602 | Berg et al. | Mar 2004 | B2 |
| 6720923 | Hayward et al. | Apr 2004 | B1 |
| 6738671 | Christophersom et al. | May 2004 | B2 |
| 6740033 | Olejniczak et al. | May 2004 | B1 |
| 6745082 | Axelgaard et al. | Jun 2004 | B2 |
| 6755783 | Cosentino | Jun 2004 | B2 |
| 6757523 | Fry | Jun 2004 | B2 |
| 6759968 | Zierolf | Jul 2004 | B2 |
| 6767200 | Sowden et al. | Jul 2004 | B2 |
| 6773429 | Sheppard et al. | Aug 2004 | B2 |
| 6800060 | Marshall | Oct 2004 | B2 |
| 6801137 | Eggers et al. | Oct 2004 | B2 |
| 6816794 | Alvi | Nov 2004 | B2 |
| 6822554 | Vrijens et al. | Nov 2004 | B2 |
| 6824512 | Warkentin et al. | Nov 2004 | B2 |
| 6836862 | Erekson et al. | Dec 2004 | B1 |
| 6839659 | Tarassenko et al. | Jan 2005 | B2 |
| 6840904 | Goldberg | Jan 2005 | B2 |
| 6842636 | Perrault | Jan 2005 | B2 |
| 6845272 | Thomsen | Jan 2005 | B1 |
| 6864780 | Doi | Mar 2005 | B2 |
| 6879810 | Bouet | Apr 2005 | B2 |
| 6888337 | Sawyers | May 2005 | B2 |
| 6889165 | Lind et al. | May 2005 | B2 |
| 6909878 | Haller | Jun 2005 | B2 |
| 6922592 | Thompson et al. | Jul 2005 | B2 |
| 6928370 | Anuzis et al. | Aug 2005 | B2 |
| 6929636 | Von Alten | Aug 2005 | B1 |
| 6937150 | Medema | Aug 2005 | B2 |
| 6942616 | Kerr | Sep 2005 | B2 |
| 6942770 | Cai et al. | Sep 2005 | B2 |
| 6946156 | Bunick | Sep 2005 | B2 |
| 6951536 | Yokoi | Oct 2005 | B2 |
| 6957107 | Rogers et al. | Oct 2005 | B2 |
| 6958603 | Kondo | Oct 2005 | B2 |
| 6960617 | Omidian et al. | Nov 2005 | B2 |
| 6968153 | Heinonen | Nov 2005 | B1 |
| 6977511 | Patel et al. | Dec 2005 | B2 |
| 6982094 | Sowden | Jan 2006 | B2 |
| 6987965 | Ng et al. | Jan 2006 | B2 |
| 6990082 | Zehavi et al. | Jan 2006 | B1 |
| 7002476 | Rapchak | Feb 2006 | B2 |
| 7004395 | Koenck | Feb 2006 | B2 |
| 7009634 | Iddan et al. | Mar 2006 | B2 |
| 7009946 | Kardach | Mar 2006 | B1 |
| 7013162 | Gorsuch | Mar 2006 | B2 |
| 7016648 | Haller | Mar 2006 | B2 |
| 7020508 | Stivoric | Mar 2006 | B2 |
| 7024248 | Penner et al. | Apr 2006 | B2 |
| 7031745 | Shen | Apr 2006 | B2 |
| 7031857 | Tarassenko et al. | Apr 2006 | B2 |
| 7039453 | Mullick | May 2006 | B2 |
| 7044911 | Drinan et al. | May 2006 | B2 |
| 7046649 | Awater et al. | May 2006 | B2 |
| 7061236 | Britton | Jun 2006 | B2 |
| 7083578 | Lewkowicz | Aug 2006 | B2 |
| 7116252 | Teraguchi | Oct 2006 | B2 |
| 7118531 | Krill | Oct 2006 | B2 |
| 7122143 | Sowden et al. | Oct 2006 | B2 |
| 7127300 | Mazar et al. | Oct 2006 | B2 |
| 7146228 | Nielsen | Dec 2006 | B2 |
| 7146449 | Do et al. | Dec 2006 | B2 |
| 7149581 | Goedeke et al. | Dec 2006 | B2 |
| 7154071 | Sattler et al. | Dec 2006 | B2 |
| 7155232 | Godfrey et al. | Dec 2006 | B2 |
| 7160258 | Imran | Jan 2007 | B2 |
| 7164942 | Avrahami | Jan 2007 | B2 |
| 7171166 | Ng et al. | Jan 2007 | B2 |
| 7171177 | Park et al. | Jan 2007 | B2 |
| 7171259 | Rytky | Jan 2007 | B2 |
| 7176784 | Gilbert et al. | Feb 2007 | B2 |
| 7187960 | Abreu | Mar 2007 | B2 |
| 7188199 | Leung et al. | Mar 2007 | B2 |
| 7188767 | Penuela | Mar 2007 | B2 |
| 7192397 | Lewkowicz | Mar 2007 | B2 |
| 7194038 | Inkinen | Mar 2007 | B1 |
| 7196495 | Burcham | Mar 2007 | B1 |
| 7206630 | Tarler | Apr 2007 | B1 |
| 7209790 | Thompson et al. | Apr 2007 | B2 |
| 7215660 | Perlman | May 2007 | B2 |
| 7215991 | Besson | May 2007 | B2 |
| 7218967 | Bergelson | May 2007 | B2 |
| 7231451 | Law | Jun 2007 | B2 |
| 7243118 | Lou | Jul 2007 | B2 |
| 7246521 | Kim | Jul 2007 | B2 |
| 7249212 | Do | Jul 2007 | B2 |
| 7252792 | Perrault | Aug 2007 | B2 |
| 7253716 | Lovoi et al. | Aug 2007 | B2 |
| 7261690 | Teller | Aug 2007 | B2 |
| 7270633 | Goscha | Sep 2007 | B1 |
| 7273454 | Raymond et al. | Sep 2007 | B2 |
| 7289855 | Nghiem | Oct 2007 | B2 |
| 7291497 | Holmes | Nov 2007 | B2 |
| 7292139 | Mazar et al. | Nov 2007 | B2 |
| 7294105 | Islam | Nov 2007 | B1 |
| 7311665 | Hawthorne | Dec 2007 | B2 |
| 7313163 | Liu | Dec 2007 | B2 |
| 7317378 | Jarvis et al. | Jan 2008 | B2 |
| 7318808 | Tarassenko et al. | Jan 2008 | B2 |
| 7336929 | Yasuda | Feb 2008 | B2 |
| 7342895 | Serpa | Mar 2008 | B2 |
| 7346380 | Axelgaard et al. | Mar 2008 | B2 |
| 7349722 | Witkowski et al. | Mar 2008 | B2 |
| 7352998 | Palin | Apr 2008 | B2 |
| 7353258 | Washburn | Apr 2008 | B2 |
| 7357891 | Yang et al. | Apr 2008 | B2 |
| 7359674 | Markki | Apr 2008 | B2 |
| 7366558 | Virtanen et al. | Apr 2008 | B2 |
| 7368190 | Heller et al. | May 2008 | B2 |
| 7368191 | Andelman et al. | May 2008 | B2 |
| 7373196 | Ryu et al. | May 2008 | B2 |
| 7375739 | Robbins | May 2008 | B2 |
| 7376435 | McGowan | May 2008 | B2 |
| 7382247 | Welch et al. | Jun 2008 | B2 |
| 7382263 | Danowski et al. | Jun 2008 | B2 |
| 7387607 | Holt | Jun 2008 | B2 |
| 7388903 | Godfrey et al. | Jun 2008 | B2 |
| 7389088 | Kim | Jun 2008 | B2 |
| 7392015 | Farlow | Jun 2008 | B1 |
| 7395106 | Ryu et al. | Jul 2008 | B2 |
| 7396330 | Banet | Jul 2008 | B2 |
| 7404968 | Abrams et al. | Jul 2008 | B2 |
| 7413544 | Kerr | Aug 2008 | B2 |
| 7414534 | Kroll et al. | Aug 2008 | B1 |
| 7414543 | Rye et al. | Aug 2008 | B2 |
| 7415242 | Ngan | Aug 2008 | B1 |
| 7424268 | Diener | Sep 2008 | B2 |
| 7424319 | Muehlsteff | Sep 2008 | B2 |
| 7427266 | Ayer et al. | Sep 2008 | B2 |
| 7442164 | Berrang et al. | Oct 2008 | B2 |
| 7443290 | Takiguchi | Oct 2008 | B2 |
| 7458887 | Kurosawa | Dec 2008 | B2 |
| 7469838 | Brooks et al. | Dec 2008 | B2 |
| 7471665 | Perlman | Dec 2008 | B2 |
| 7471992 | Schmidt et al. | Dec 2008 | B2 |
| 7492128 | Shen | Feb 2009 | B2 |
| 7499674 | Salokannel | Mar 2009 | B2 |
| 7510121 | Koenck | Mar 2009 | B2 |
| 7512448 | Malick | Mar 2009 | B2 |
| 7515043 | Welch | Apr 2009 | B2 |
| 7519416 | Sula et al. | Apr 2009 | B2 |
| 7523756 | Minai | Apr 2009 | B2 |
| 7525426 | Edelstein | Apr 2009 | B2 |
| 7527807 | Choi et al. | May 2009 | B2 |
| 7537590 | Santini, Jr. et al. | May 2009 | B2 |
| 7539533 | Tran | May 2009 | B2 |
| 7542878 | Nanikashvili | Jun 2009 | B2 |
| 7547278 | Miyazaki et al. | Jun 2009 | B2 |
| 7551590 | Haller | Jun 2009 | B2 |
| 7554452 | Cole | Jun 2009 | B2 |
| 7558620 | Ishibashi | Jul 2009 | B2 |
| 7575005 | Mumford | Aug 2009 | B2 |
| 7616111 | Covannon | Nov 2009 | B2 |
| 7617001 | Penner et al. | Nov 2009 | B2 |
| 7626387 | Adachi | Dec 2009 | B2 |
| 7639473 | Hsu et al. | Dec 2009 | B2 |
| 7640802 | King et al. | Jan 2010 | B2 |
| 7645262 | Greenberg et al. | Jan 2010 | B2 |
| 7647112 | Tracey | Jan 2010 | B2 |
| 7647185 | Tarassenko et al. | Jan 2010 | B2 |
| 7653031 | Godfrey et al. | Jan 2010 | B2 |
| 7672714 | Kuo | Mar 2010 | B2 |
| 7673679 | Harrison et al. | Mar 2010 | B2 |
| 7678043 | Gilad | Mar 2010 | B2 |
| 7686839 | Parker | Mar 2010 | B2 |
| 7697994 | VanDanacker et al. | Apr 2010 | B2 |
| 7720036 | Sadri | May 2010 | B2 |
| 7729776 | Von Arx et al. | Jun 2010 | B2 |
| 7733224 | Tran | Jun 2010 | B2 |
| 7736318 | Costentino | Jun 2010 | B2 |
| 7756587 | Penner et al. | Jul 2010 | B2 |
| 7760104 | Asp | Jul 2010 | B2 |
| 7782991 | Sobchak et al. | Aug 2010 | B2 |
| 7796043 | Euliano et al. | Sep 2010 | B2 |
| 7797033 | D'Andrea et al. | Sep 2010 | B2 |
| 7809399 | Lu | Oct 2010 | B2 |
| 7844341 | Von Arx et al. | Nov 2010 | B2 |
| 7881799 | Greenberg et al. | Feb 2011 | B2 |
| 7975587 | Schneider | Jul 2011 | B2 |
| 7978064 | Zdeblick et al. | Jul 2011 | B2 |
| 7983189 | Bugenhagen | Jul 2011 | B2 |
| 8036731 | Kimchy et al. | Oct 2011 | B2 |
| 8036748 | Zdeblick et al. | Oct 2011 | B2 |
| 8054047 | Chen et al. | Nov 2011 | B2 |
| 8054140 | Fleming et al. | Nov 2011 | B2 |
| 8055334 | Savage et al. | Nov 2011 | B2 |
| 8082919 | Brunnberg et al. | Dec 2011 | B2 |
| 8119045 | Schmidt et al. | Feb 2012 | B2 |
| 8131376 | Faraji et al. | Mar 2012 | B1 |
| 8177611 | Kang | May 2012 | B2 |
| 8185191 | Shapiro et al. | May 2012 | B1 |
| 8185646 | Headley | May 2012 | B2 |
| 8200320 | Kovacs | Jun 2012 | B2 |
| 8207731 | Moskalenko | Jun 2012 | B2 |
| 8224596 | Agrawal et al. | Jul 2012 | B2 |
| 8253586 | Matak | Aug 2012 | B1 |
| 8254853 | Rofougaran | Aug 2012 | B2 |
| 8271146 | Heber et al. | Sep 2012 | B2 |
| 8298574 | Tsabari et al. | Oct 2012 | B2 |
| 8343068 | Najafi et al. | Jan 2013 | B2 |
| 8374698 | Ok et al. | Feb 2013 | B2 |
| 8389003 | Mintchev et al. | Mar 2013 | B2 |
| 8404275 | Habboushe | Mar 2013 | B2 |
| 8425492 | Herbert et al. | Apr 2013 | B2 |
| 8443214 | Lee et al. | May 2013 | B2 |
| 8454528 | Yuen et al. | Jun 2013 | B2 |
| 8532776 | Greenberg et al. | Sep 2013 | B2 |
| 8540664 | Robertson et al. | Sep 2013 | B2 |
| 8547248 | Zdeblick et al. | Oct 2013 | B2 |
| 8558563 | Zdeblick | Oct 2013 | B2 |
| 8564432 | Covannon et al. | Oct 2013 | B2 |
| 8597186 | Hafezi et al. | Dec 2013 | B2 |
| 8634838 | Hellwig et al. | Jan 2014 | B2 |
| 8647358 | Brister et al. | Feb 2014 | B2 |
| 8660645 | Stevenson et al. | Feb 2014 | B2 |
| 8668643 | Kinast | Mar 2014 | B2 |
| 8685451 | Toneguzzo et al. | Apr 2014 | B2 |
| 8697057 | Van Epps et al. | Apr 2014 | B2 |
| 8698006 | Bealka et al. | Apr 2014 | B2 |
| 8758237 | Sherman et al. | Jun 2014 | B2 |
| 8784308 | Duck et al. | Jul 2014 | B2 |
| 8802183 | Frank et al. | Aug 2014 | B2 |
| 8816847 | Zdeblick et al. | Aug 2014 | B2 |
| 8836513 | Hafezi et al. | Sep 2014 | B2 |
| 8838217 | Myr | Sep 2014 | B2 |
| 8858432 | Robertson | Oct 2014 | B2 |
| 8908943 | Berry et al. | Dec 2014 | B2 |
| 8912908 | Berkman et al. | Dec 2014 | B2 |
| 8926509 | Magar et al. | Jan 2015 | B2 |
| 8932221 | Colliou et al. | Jan 2015 | B2 |
| 8945005 | Hafezi et al. | Feb 2015 | B2 |
| 8951234 | Hafezi et al. | Feb 2015 | B2 |
| 8989837 | Weinstein et al. | Mar 2015 | B2 |
| 9031658 | Chiao et al. | May 2015 | B2 |
| 9088168 | Mach et al. | Jul 2015 | B2 |
| 9107806 | Hafezi et al. | Aug 2015 | B2 |
| 9119554 | Robertson et al. | Sep 2015 | B2 |
| 9119918 | Robertson et al. | Sep 2015 | B2 |
| 9149423 | Duck et al. | Oct 2015 | B2 |
| 9158890 | Meredith et al. | Oct 2015 | B2 |
| 9161707 | Hafezi et al. | Oct 2015 | B2 |
| 9189941 | Eschelman et al. | Nov 2015 | B2 |
| 9226663 | Fei | Jan 2016 | B2 |
| 9226679 | Balda | Jan 2016 | B2 |
| 9268909 | Jani et al. | Feb 2016 | B2 |
| 9270025 | Robertson et al. | Feb 2016 | B2 |
| 9271897 | Costello et al. | Mar 2016 | B2 |
| 9277864 | Yang et al. | Mar 2016 | B2 |
| 9433371 | Hafezi et al. | Sep 2016 | B2 |
| 9439599 | Thompson et al. | Sep 2016 | B2 |
| 9517012 | Lane et al. | Dec 2016 | B2 |
| 9599679 | Taylor et al. | Mar 2017 | B2 |
| 9741975 | Laulicht et al. | Aug 2017 | B2 |
| 9756874 | Arne et al. | Sep 2017 | B2 |
| 9968284 | Vidalis et al. | May 2018 | B2 |
| 20010027331 | Thompson | Oct 2001 | A1 |
| 20010044588 | Mault | Nov 2001 | A1 |
| 20010051766 | Gazdinski | Dec 2001 | A1 |
| 20020002326 | Causey et al. | Jan 2002 | A1 |
| 20020026111 | Ackerman | Feb 2002 | A1 |
| 20020032384 | Raymond et al. | Mar 2002 | A1 |
| 20020032385 | Raymond et al. | Mar 2002 | A1 |
| 20020040278 | Anuzis et al. | Apr 2002 | A1 |
| 20020077620 | Sweeney et al. | Jun 2002 | A1 |
| 20020128934 | Shaer | Sep 2002 | A1 |
| 20020132226 | Nair | Sep 2002 | A1 |
| 20020136744 | McGlynn et al. | Sep 2002 | A1 |
| 20020179921 | Cohn | Dec 2002 | A1 |
| 20020192159 | Reitberg | Dec 2002 | A1 |
| 20020193669 | Glukhovsky | Dec 2002 | A1 |
| 20020198470 | Imran et al. | Dec 2002 | A1 |
| 20030017826 | Fishman et al. | Jan 2003 | A1 |
| 20030023150 | Yokoi et al. | Jan 2003 | A1 |
| 20030028226 | Thompson | Feb 2003 | A1 |
| 20030062551 | Chen et al. | Apr 2003 | A1 |
| 20030065536 | Hansen | Apr 2003 | A1 |
| 20030076179 | Branch et al. | Apr 2003 | A1 |
| 20030083559 | Thompson | May 2003 | A1 |
| 20030091625 | Hariharan et al. | May 2003 | A1 |
| 20030126593 | Mault | Jul 2003 | A1 |
| 20030130714 | Nielsen et al. | Jul 2003 | A1 |
| 20030135128 | Suffin et al. | Jul 2003 | A1 |
| 20030135392 | Vrijens et al. | Jul 2003 | A1 |
| 20030152622 | Louie-Helm et al. | Aug 2003 | A1 |
| 20030158466 | Lynn et al. | Aug 2003 | A1 |
| 20030158756 | Abramson | Aug 2003 | A1 |
| 20030162556 | Libes | Aug 2003 | A1 |
| 20030164401 | Andreasson et al. | Sep 2003 | A1 |
| 20030167000 | Mullick et al. | Sep 2003 | A1 |
| 20030171791 | KenKnight | Sep 2003 | A1 |
| 20030171898 | Tarassenko et al. | Sep 2003 | A1 |
| 20030181788 | Yokoi et al. | Sep 2003 | A1 |
| 20030185286 | Yuen | Oct 2003 | A1 |
| 20030187337 | Tarassenko et al. | Oct 2003 | A1 |
| 20030187338 | Say et al. | Oct 2003 | A1 |
| 20030195403 | Berner et al. | Oct 2003 | A1 |
| 20030213495 | Fujita et al. | Nov 2003 | A1 |
| 20030214579 | Iddan | Nov 2003 | A1 |
| 20030216622 | Meron et al. | Nov 2003 | A1 |
| 20030216625 | Phipps | Nov 2003 | A1 |
| 20030216666 | Ericson et al. | Nov 2003 | A1 |
| 20030216729 | Marchitto | Nov 2003 | A1 |
| 20030219484 | Sowden et al. | Nov 2003 | A1 |
| 20030232895 | Omidian et al. | Dec 2003 | A1 |
| 20040008123 | Carrender et al. | Jan 2004 | A1 |
| 20040018476 | LaDue | Jan 2004 | A1 |
| 20040034295 | Salganicoff | Feb 2004 | A1 |
| 20040049245 | Gass | Mar 2004 | A1 |
| 20040073095 | Causey et al. | Apr 2004 | A1 |
| 20040073454 | Urquhart et al. | Apr 2004 | A1 |
| 20040077995 | Ferek-Petric | Apr 2004 | A1 |
| 20040082982 | Gord et al. | Apr 2004 | A1 |
| 20040087839 | Raymond et al. | May 2004 | A1 |
| 20040092801 | Drakulic | May 2004 | A1 |
| 20040106859 | Say et al. | Jun 2004 | A1 |
| 20040115507 | Potter et al. | Jun 2004 | A1 |
| 20040115517 | Fukada et al. | Jun 2004 | A1 |
| 20040121015 | Chidlaw et al. | Jun 2004 | A1 |
| 20040148140 | Tarassenko et al. | Jul 2004 | A1 |
| 20040153007 | Harris | Aug 2004 | A1 |
| 20040167226 | Serafini | Aug 2004 | A1 |
| 20040167465 | Mihai et al. | Aug 2004 | A1 |
| 20040167801 | Say et al. | Aug 2004 | A1 |
| 20040193020 | Chiba | Sep 2004 | A1 |
| 20040193029 | Gluhovsky | Sep 2004 | A1 |
| 20040193446 | Mayer et al. | Sep 2004 | A1 |
| 20040199222 | Sun et al. | Oct 2004 | A1 |
| 20040215084 | Shimizu et al. | Oct 2004 | A1 |
| 20040218683 | Batra | Nov 2004 | A1 |
| 20040220643 | Schmidt | Nov 2004 | A1 |
| 20040224644 | Wu | Nov 2004 | A1 |
| 20040225199 | Evanyk | Nov 2004 | A1 |
| 20040253304 | Gross et al. | Dec 2004 | A1 |
| 20040258571 | Lee et al. | Dec 2004 | A1 |
| 20040259899 | Sanghvi et al. | Dec 2004 | A1 |
| 20040260154 | Sidelnik | Dec 2004 | A1 |
| 20050003074 | Brown et al. | Jan 2005 | A1 |
| 20050017841 | Doi | Jan 2005 | A1 |
| 20050020887 | Goldberg | Jan 2005 | A1 |
| 20050021370 | Riff | Jan 2005 | A1 |
| 20050024198 | Ward | Feb 2005 | A1 |
| 20050027205 | Tarassenko et al. | Feb 2005 | A1 |
| 20050038321 | Fujita et al. | Feb 2005 | A1 |
| 20050043634 | Yokoi et al. | Feb 2005 | A1 |
| 20050043894 | Fernandez | Feb 2005 | A1 |
| 20050054897 | Hashimoto et al. | Mar 2005 | A1 |
| 20050055014 | Coppeta et al. | Mar 2005 | A1 |
| 20050062644 | Leci | Mar 2005 | A1 |
| 20050065407 | Nakamura et al. | Mar 2005 | A1 |
| 20050070778 | Lackey | Mar 2005 | A1 |
| 20050075145 | Dvorak et al. | Apr 2005 | A1 |
| 20050090753 | Goor et al. | Apr 2005 | A1 |
| 20050092108 | Andermo | May 2005 | A1 |
| 20050096514 | Starkebaum | May 2005 | A1 |
| 20050096562 | Delalic et al. | May 2005 | A1 |
| 20050101843 | Quinn | May 2005 | A1 |
| 20050101872 | Sattler | May 2005 | A1 |
| 20050115561 | Stahmann et al. | Jun 2005 | A1 |
| 20050116820 | Goldreich | Jun 2005 | A1 |
| 20050117389 | Worledge | Jun 2005 | A1 |
| 20050121322 | Say et al. | Jun 2005 | A1 |
| 20050131281 | Ayer et al. | Jun 2005 | A1 |
| 20050143623 | Kojima | Jun 2005 | A1 |
| 20050146594 | Nakatani et al. | Jul 2005 | A1 |
| 20050148883 | Boesen | Jul 2005 | A1 |
| 20050154428 | Bruinsma | Jul 2005 | A1 |
| 20050156709 | Gilbert et al. | Jul 2005 | A1 |
| 20050165323 | Montgomery | Jul 2005 | A1 |
| 20050177069 | Takizawa | Aug 2005 | A1 |
| 20050182389 | LaPorte | Aug 2005 | A1 |
| 20050187789 | Hatlestad et al. | Aug 2005 | A1 |
| 20050192489 | Marshall | Sep 2005 | A1 |
| 20050197680 | DelMain et al. | Sep 2005 | A1 |
| 20050208251 | Aisenbrey | Sep 2005 | A1 |
| 20050228268 | Cole | Oct 2005 | A1 |
| 20050234307 | Heinonen | Oct 2005 | A1 |
| 20050240305 | Bogash et al. | Oct 2005 | A1 |
| 20050245794 | Dinsmoor | Nov 2005 | A1 |
| 20050259768 | Yang et al. | Nov 2005 | A1 |
| 20050261559 | Mumford | Nov 2005 | A1 |
| 20050267556 | Shuros et al. | Dec 2005 | A1 |
| 20050267756 | Schultz et al. | Dec 2005 | A1 |
| 20050277912 | John | Dec 2005 | A1 |
| 20050277999 | Strother et al. | Dec 2005 | A1 |
| 20050279054 | Mauze et al. | Dec 2005 | A1 |
| 20050280539 | Pettus | Dec 2005 | A1 |
| 20050285746 | Sengupta | Dec 2005 | A1 |
| 20050288594 | Lewkowicz et al. | Dec 2005 | A1 |
| 20060001496 | Abrosimov et al. | Jan 2006 | A1 |
| 20060028727 | Moon et al. | Feb 2006 | A1 |
| 20060036134 | Tarassenko et al. | Feb 2006 | A1 |
| 20060058602 | Kwiatkowski et al. | Mar 2006 | A1 |
| 20060061472 | Lovoi et al. | Mar 2006 | A1 |
| 20060065713 | Kingery | Mar 2006 | A1 |
| 20060068006 | Begleiter | Mar 2006 | A1 |
| 20060074283 | Henderson | Apr 2006 | A1 |
| 20060074319 | Barnes et al. | Apr 2006 | A1 |
| 20060078765 | Yang et al. | Apr 2006 | A1 |
| 20060095091 | Drew | May 2006 | A1 |
| 20060095093 | Bettesh et al. | May 2006 | A1 |
| 20060100533 | Han | May 2006 | A1 |
| 20060109058 | Keating | May 2006 | A1 |
| 20060110962 | Powell | May 2006 | A1 |
| 20060122474 | Teller et al. | Jun 2006 | A1 |
| 20060122494 | Bouchoucha | Jun 2006 | A1 |
| 20060122667 | Chavan et al. | Jun 2006 | A1 |
| 20060129060 | Lee et al. | Jun 2006 | A1 |
| 20060136266 | Tarassenko et al. | Jun 2006 | A1 |
| 20060142648 | Banet | Jun 2006 | A1 |
| 20060145876 | Kimura | Jul 2006 | A1 |
| 20060148254 | McLean | Jul 2006 | A1 |
| 20060149339 | Burnes | Jul 2006 | A1 |
| 20060155174 | Glukhovsky et al. | Jul 2006 | A1 |
| 20060155183 | Kroecker | Jul 2006 | A1 |
| 20060161225 | Sormann et al. | Jul 2006 | A1 |
| 20060179949 | Kim | Aug 2006 | A1 |
| 20060183993 | Horn | Aug 2006 | A1 |
| 20060184092 | Atanasoska et al. | Aug 2006 | A1 |
| 20060204738 | Dubrow et al. | Sep 2006 | A1 |
| 20060210626 | Spaeder | Sep 2006 | A1 |
| 20060216603 | Choi | Sep 2006 | A1 |
| 20060218011 | Walker | Sep 2006 | A1 |
| 20060235489 | Drew | Oct 2006 | A1 |
| 20060243288 | Kim et al. | Nov 2006 | A1 |
| 20060247505 | Siddiqui | Nov 2006 | A1 |
| 20060253005 | Drinan | Nov 2006 | A1 |
| 20060270346 | Ibrahim | Nov 2006 | A1 |
| 20060273882 | Posamentier | Dec 2006 | A1 |
| 20060276702 | McGinnis | Dec 2006 | A1 |
| 20060280227 | Pinkney | Dec 2006 | A1 |
| 20060282001 | Noel | Dec 2006 | A1 |
| 20060289640 | Mercure | Dec 2006 | A1 |
| 20060293607 | Alt | Dec 2006 | A1 |
| 20070000776 | Karube et al. | Jan 2007 | A1 |
| 20070002038 | Suzuki | Jan 2007 | A1 |
| 20070006636 | King et al. | Jan 2007 | A1 |
| 20070008113 | Spoonhower et al. | Jan 2007 | A1 |
| 20070016089 | Fischell et al. | Jan 2007 | A1 |
| 20070027386 | Such | Feb 2007 | A1 |
| 20070027388 | Chou | Feb 2007 | A1 |
| 20070029195 | Li et al. | Feb 2007 | A1 |
| 20070038054 | Zhou | Feb 2007 | A1 |
| 20070049339 | Barak et al. | Mar 2007 | A1 |
| 20070055098 | Shimizu et al. | Mar 2007 | A1 |
| 20070060797 | Ball | Mar 2007 | A1 |
| 20070060800 | Drinan et al. | Mar 2007 | A1 |
| 20070066929 | Ferren et al. | Mar 2007 | A1 |
| 20070073353 | Rooney et al. | Mar 2007 | A1 |
| 20070096765 | Kagan | May 2007 | A1 |
| 20070106346 | Bergelson | May 2007 | A1 |
| 20070123772 | Euliano | May 2007 | A1 |
| 20070129622 | Bourget | Jun 2007 | A1 |
| 20070130287 | Kumar | Jun 2007 | A1 |
| 20070135803 | Belson | Jun 2007 | A1 |
| 20070142721 | Berner et al. | Jun 2007 | A1 |
| 20070156016 | Betesh | Jul 2007 | A1 |
| 20070160789 | Merical | Jul 2007 | A1 |
| 20070162089 | Mosesov | Jul 2007 | A1 |
| 20070162090 | Penner | Jul 2007 | A1 |
| 20070167495 | Brown et al. | Jul 2007 | A1 |
| 20070167848 | Kuo et al. | Jul 2007 | A1 |
| 20070173701 | Al-Ali | Jul 2007 | A1 |
| 20070179347 | Tarassenko et al. | Aug 2007 | A1 |
| 20070179371 | Peyser et al. | Aug 2007 | A1 |
| 20070185393 | Zhou | Aug 2007 | A1 |
| 20070191002 | Ge | Aug 2007 | A1 |
| 20070196456 | Stevens | Aug 2007 | A1 |
| 20070207793 | Myer | Sep 2007 | A1 |
| 20070208233 | Kovacs | Sep 2007 | A1 |
| 20070213659 | Trovato et al. | Sep 2007 | A1 |
| 20070237719 | Jones | Oct 2007 | A1 |
| 20070244370 | Kuo et al. | Oct 2007 | A1 |
| 20070255198 | Leong et al. | Nov 2007 | A1 |
| 20070255330 | Lee | Nov 2007 | A1 |
| 20070270672 | Hayter | Nov 2007 | A1 |
| 20070279217 | Venkatraman | Dec 2007 | A1 |
| 20070282174 | Sabatino | Dec 2007 | A1 |
| 20070282177 | Pilz | Dec 2007 | A1 |
| 20070299480 | Hill | Dec 2007 | A1 |
| 20080000804 | Carey et al. | Jan 2008 | A1 |
| 20080014866 | Lipowshi | Jan 2008 | A1 |
| 20080020037 | Robertson et al. | Jan 2008 | A1 |
| 20080021519 | DeGeest | Jan 2008 | A1 |
| 20080021521 | Shah | Jan 2008 | A1 |
| 20080027679 | Shklarski | Jan 2008 | A1 |
| 20080033273 | Zhou | Feb 2008 | A1 |
| 20080038588 | Lee | Feb 2008 | A1 |
| 20080039700 | Drinan et al. | Feb 2008 | A1 |
| 20080045843 | Tsuji et al. | Feb 2008 | A1 |
| 20080046038 | Hill | Feb 2008 | A1 |
| 20080051647 | Wu et al. | Feb 2008 | A1 |
| 20080051667 | Goldreich | Feb 2008 | A1 |
| 20080058614 | Banet | Mar 2008 | A1 |
| 20080062856 | Feher | Mar 2008 | A1 |
| 20080065168 | Bitton et al. | Mar 2008 | A1 |
| 20080074307 | Boric-Lubecke | Mar 2008 | A1 |
| 20080077015 | Botic-Lubecke | Mar 2008 | A1 |
| 20080077028 | Schaldach et al. | Mar 2008 | A1 |
| 20080077188 | Denker et al. | Mar 2008 | A1 |
| 20080091089 | Guillory et al. | Apr 2008 | A1 |
| 20080091114 | Min | Apr 2008 | A1 |
| 20080097549 | Colbaugh | Apr 2008 | A1 |
| 20080097917 | Dicks | Apr 2008 | A1 |
| 20080103440 | Ferren et al. | May 2008 | A1 |
| 20080112885 | Okunev et al. | May 2008 | A1 |
| 20080114224 | Bandy et al. | May 2008 | A1 |
| 20080119705 | Patel | May 2008 | A1 |
| 20080119716 | Boric-Lubecke | May 2008 | A1 |
| 20080121825 | Trovato et al. | May 2008 | A1 |
| 20080137566 | Marholev | Jun 2008 | A1 |
| 20080139907 | Rao et al. | Jun 2008 | A1 |
| 20080140403 | Hughes et al. | Jun 2008 | A1 |
| 20080146871 | Arneson et al. | Jun 2008 | A1 |
| 20080146889 | Young | Jun 2008 | A1 |
| 20080146892 | LeBoeuf | Jun 2008 | A1 |
| 20080154104 | Lamego | Jun 2008 | A1 |
| 20080166992 | Ricordi | Jul 2008 | A1 |
| 20080175898 | Jones et al. | Jul 2008 | A1 |
| 20080183245 | Van Oort | Jul 2008 | A1 |
| 20080188837 | Belsky et al. | Aug 2008 | A1 |
| 20080194912 | Trovato et al. | Aug 2008 | A1 |
| 20080208009 | Shklarski | Aug 2008 | A1 |
| 20080214901 | Gehman | Sep 2008 | A1 |
| 20080214985 | Yanaki | Sep 2008 | A1 |
| 20080243020 | Chou | Oct 2008 | A1 |
| 20080249360 | Li | Oct 2008 | A1 |
| 20080262320 | Schaefer et al. | Oct 2008 | A1 |
| 20080262336 | Ryu | Oct 2008 | A1 |
| 20080269664 | Trovato et al. | Oct 2008 | A1 |
| 20080275312 | Mosesov | Nov 2008 | A1 |
| 20080284599 | Zdeblick et al. | Nov 2008 | A1 |
| 20080288027 | Kroll | Nov 2008 | A1 |
| 20080294020 | Sapounas | Nov 2008 | A1 |
| 20080299197 | Toneguzzo et al. | Dec 2008 | A1 |
| 20080300572 | Rankers | Dec 2008 | A1 |
| 20080303638 | Nguyen | Dec 2008 | A1 |
| 20080306357 | Korman | Dec 2008 | A1 |
| 20080306359 | Zdeblick et al. | Dec 2008 | A1 |
| 20080306360 | Robertson et al. | Dec 2008 | A1 |
| 20080311852 | Hansen | Dec 2008 | A1 |
| 20080312522 | Rowlandson | Dec 2008 | A1 |
| 20080316020 | Robertson | Dec 2008 | A1 |
| 20090009330 | Sakama et al. | Jan 2009 | A1 |
| 20090009332 | Nunez et al. | Jan 2009 | A1 |
| 20090024045 | Prakash | Jan 2009 | A1 |
| 20090024112 | Edwards et al. | Jan 2009 | A1 |
| 20090030293 | Cooper et al. | Jan 2009 | A1 |
| 20090030297 | Miller | Jan 2009 | A1 |
| 20090034209 | Joo | Feb 2009 | A1 |
| 20090043171 | Rule | Feb 2009 | A1 |
| 20090047357 | Tomohira et al. | Feb 2009 | A1 |
| 20090048498 | Riskey | Feb 2009 | A1 |
| 20090062634 | Say et al. | Mar 2009 | A1 |
| 20090062670 | Sterling | Mar 2009 | A1 |
| 20090062730 | Woo | Mar 2009 | A1 |
| 20090069642 | Gao | Mar 2009 | A1 |
| 20090069655 | Say et al. | Mar 2009 | A1 |
| 20090069656 | Say et al. | Mar 2009 | A1 |
| 20090069657 | Say et al. | Mar 2009 | A1 |
| 20090069658 | Say et al. | Mar 2009 | A1 |
| 20090069724 | Otto et al. | Mar 2009 | A1 |
| 20090076343 | James | Mar 2009 | A1 |
| 20090076350 | Bly et al. | Mar 2009 | A1 |
| 20090082645 | Hafezi et al. | Mar 2009 | A1 |
| 20090087483 | Sison | Apr 2009 | A1 |
| 20090088618 | Ameson | Apr 2009 | A1 |
| 20090099435 | Say et al. | Apr 2009 | A1 |
| 20090105561 | Boydon et al. | Apr 2009 | A1 |
| 20090110148 | Zhang | Apr 2009 | A1 |
| 20090112626 | Talbot | Apr 2009 | A1 |
| 20090124871 | Arshak | May 2009 | A1 |
| 20090124965 | Greenberg et al. | May 2009 | A1 |
| 20090131774 | Sweitzer | May 2009 | A1 |
| 20090135886 | Robertson et al. | May 2009 | A1 |
| 20090142853 | Warrington et al. | Jun 2009 | A1 |
| 20090149839 | Hyde et al. | Jun 2009 | A1 |
| 20090157113 | Marcotte | Jun 2009 | A1 |
| 20090157358 | Kim | Jun 2009 | A1 |
| 20090161602 | Matsumoto | Jun 2009 | A1 |
| 20090163789 | Say et al. | Jun 2009 | A1 |
| 20090171180 | Pering | Jul 2009 | A1 |
| 20090171420 | Brown et al. | Jul 2009 | A1 |
| 20090173628 | Say et al. | Jul 2009 | A1 |
| 20090177055 | Say et al. | Jul 2009 | A1 |
| 20090177056 | Say et al. | Jul 2009 | A1 |
| 20090177057 | Say et al. | Jul 2009 | A1 |
| 20090177058 | Say et al. | Jul 2009 | A1 |
| 20090177059 | Say et al. | Jul 2009 | A1 |
| 20090177060 | Say et al. | Jul 2009 | A1 |
| 20090177061 | Say et al. | Jul 2009 | A1 |
| 20090177062 | Say et al. | Jul 2009 | A1 |
| 20090177063 | Say et al. | Jul 2009 | A1 |
| 20090177064 | Say et al. | Jul 2009 | A1 |
| 20090177065 | Say et al. | Jul 2009 | A1 |
| 20090177066 | Say et al. | Jul 2009 | A1 |
| 20090182206 | Najafi | Jul 2009 | A1 |
| 20090182207 | Riskey et al. | Jul 2009 | A1 |
| 20090182212 | Say et al. | Jul 2009 | A1 |
| 20090182213 | Say et al. | Jul 2009 | A1 |
| 20090182214 | Say et al. | Jul 2009 | A1 |
| 20090182215 | Say et al. | Jul 2009 | A1 |
| 20090182388 | Von Arx | Jul 2009 | A1 |
| 20090187088 | Say et al. | Jul 2009 | A1 |
| 20090187089 | Say et al. | Jul 2009 | A1 |
| 20090187090 | Say et al. | Jul 2009 | A1 |
| 20090187091 | Say et al. | Jul 2009 | A1 |
| 20090187092 | Say et al. | Jul 2009 | A1 |
| 20090187093 | Say et al. | Jul 2009 | A1 |
| 20090187094 | Say et al. | Jul 2009 | A1 |
| 20090187095 | Say et al. | Jul 2009 | A1 |
| 20090187381 | King et al. | Jul 2009 | A1 |
| 20090192351 | Nishino | Jul 2009 | A1 |
| 20090192368 | Say et al. | Jul 2009 | A1 |
| 20090192369 | Say et al. | Jul 2009 | A1 |
| 20090192370 | Say et al. | Jul 2009 | A1 |
| 20090192371 | Say et al. | Jul 2009 | A1 |
| 20090192372 | Say et al. | Jul 2009 | A1 |
| 20090192373 | Say et al. | Jul 2009 | A1 |
| 20090192374 | Say et al. | Jul 2009 | A1 |
| 20090192375 | Say et al. | Jul 2009 | A1 |
| 20090192376 | Say et al. | Jul 2009 | A1 |
| 20090192377 | Say et al. | Jul 2009 | A1 |
| 20090192378 | Say et al. | Jul 2009 | A1 |
| 20090192379 | Say et al. | Jul 2009 | A1 |
| 20090194747 | Zou et al. | Aug 2009 | A1 |
| 20090197068 | Yamaguchi et al. | Aug 2009 | A1 |
| 20090198115 | Say et al. | Aug 2009 | A1 |
| 20090198116 | Say et al. | Aug 2009 | A1 |
| 20090198175 | Say et al. | Aug 2009 | A1 |
| 20090203964 | Shimizu et al. | Aug 2009 | A1 |
| 20090203971 | Sciarappa | Aug 2009 | A1 |
| 20090203972 | Heneghan | Aug 2009 | A1 |
| 20090203978 | Say et al. | Aug 2009 | A1 |
| 20090204265 | Hackett | Aug 2009 | A1 |
| 20090210164 | Say et al. | Aug 2009 | A1 |
| 20090216101 | Say et al. | Aug 2009 | A1 |
| 20090216102 | Say et al. | Aug 2009 | A1 |
| 20090227204 | Robertson et al. | Sep 2009 | A1 |
| 20090227876 | Tran | Sep 2009 | A1 |
| 20090227940 | Say et al. | Sep 2009 | A1 |
| 20090227941 | Say et al. | Sep 2009 | A1 |
| 20090227988 | Wood et al. | Sep 2009 | A1 |
| 20090228214 | Say et al. | Sep 2009 | A1 |
| 20090231125 | Baldus | Sep 2009 | A1 |
| 20090234200 | Husheer | Sep 2009 | A1 |
| 20090243833 | Huang | Oct 2009 | A1 |
| 20090253960 | Takenaka et al. | Oct 2009 | A1 |
| 20090256702 | Robertson | Oct 2009 | A1 |
| 20090260212 | Schmett et al. | Oct 2009 | A1 |
| 20090264714 | Chou | Oct 2009 | A1 |
| 20090264964 | Abrahamson | Oct 2009 | A1 |
| 20090265186 | Tarassenko et al. | Oct 2009 | A1 |
| 20090273467 | Elixmann | Nov 2009 | A1 |
| 20090281539 | Selig | Nov 2009 | A1 |
| 20090287109 | Ferren et al. | Nov 2009 | A1 |
| 20090295548 | Ronkka | Dec 2009 | A1 |
| 20090296677 | Mahany | Dec 2009 | A1 |
| 20090303920 | Mahany | Dec 2009 | A1 |
| 20090306633 | Trovato et al. | Dec 2009 | A1 |
| 20090312619 | Say et al. | Dec 2009 | A1 |
| 20090318303 | Delamarche et al. | Dec 2009 | A1 |
| 20090318761 | Rabinovitz | Dec 2009 | A1 |
| 20090318779 | Tran | Dec 2009 | A1 |
| 20090318783 | Rohde | Dec 2009 | A1 |
| 20090318793 | Datta | Dec 2009 | A1 |
| 20100001841 | Cardullo | Jan 2010 | A1 |
| 20100010330 | Rankers | Jan 2010 | A1 |
| 20100033324 | Shimizu et al. | Feb 2010 | A1 |
| 20100036269 | Ferren et al. | Feb 2010 | A1 |
| 20100049004 | Edman et al. | Feb 2010 | A1 |
| 20100049006 | Magar | Feb 2010 | A1 |
| 20100049012 | Dijksman et al. | Feb 2010 | A1 |
| 20100049069 | Tarassenko et al. | Feb 2010 | A1 |
| 20100056878 | Partin | Mar 2010 | A1 |
| 20100056891 | Say et al. | Mar 2010 | A1 |
| 20100056939 | Tarassenko et al. | Mar 2010 | A1 |
| 20100057041 | Hayter | Mar 2010 | A1 |
| 20100062709 | Kato | Mar 2010 | A1 |
| 20100063438 | Bengtsson | Mar 2010 | A1 |
| 20100063841 | D'Ambrosia et al. | Mar 2010 | A1 |
| 20100069002 | Rong | Mar 2010 | A1 |
| 20100069717 | Hafezi et al. | Mar 2010 | A1 |
| 20100099967 | Say et al. | Apr 2010 | A1 |
| 20100099968 | Say et al. | Apr 2010 | A1 |
| 20100099969 | Say et al. | Apr 2010 | A1 |
| 20100100077 | Rush | Apr 2010 | A1 |
| 20100100078 | Say et al. | Apr 2010 | A1 |
| 20100106001 | Say et al. | Apr 2010 | A1 |
| 20100118853 | Godfrey | May 2010 | A1 |
| 20100139672 | Kroll et al. | Jun 2010 | A1 |
| 20100168659 | Say et al. | Jul 2010 | A1 |
| 20100179398 | Say et al. | Jul 2010 | A1 |
| 20100191073 | Tarassenko et al. | Jul 2010 | A1 |
| 20100210299 | Gorbachov | Aug 2010 | A1 |
| 20100222652 | Cho | Sep 2010 | A1 |
| 20100228113 | Solosko | Sep 2010 | A1 |
| 20100233026 | Ismagliov et al. | Sep 2010 | A1 |
| 20100234706 | Gilland | Sep 2010 | A1 |
| 20100234715 | Shin | Sep 2010 | A1 |
| 20100234914 | Shen | Sep 2010 | A1 |
| 20100245091 | Singh | Sep 2010 | A1 |
| 20100249541 | Geva et al. | Sep 2010 | A1 |
| 20100249881 | Corndorf | Sep 2010 | A1 |
| 20100256461 | Mohamedali | Oct 2010 | A1 |
| 20100259543 | Tarassenko et al. | Oct 2010 | A1 |
| 20100268048 | Say et al. | Oct 2010 | A1 |
| 20100268049 | Say et al. | Oct 2010 | A1 |
| 20100268050 | Say et al. | Oct 2010 | A1 |
| 20100274111 | Say et al. | Oct 2010 | A1 |
| 20100280345 | Say et al. | Nov 2010 | A1 |
| 20100280346 | Say et al. | Nov 2010 | A1 |
| 20100295694 | Kauffman et al. | Nov 2010 | A1 |
| 20100297640 | Kumar et al. | Nov 2010 | A1 |
| 20100298650 | Moon et al. | Nov 2010 | A1 |
| 20100298668 | Hafezi et al. | Nov 2010 | A1 |
| 20100298730 | Tarassenko et al. | Nov 2010 | A1 |
| 20100312188 | Robertson et al. | Dec 2010 | A1 |
| 20100312580 | Tarassenko et al. | Dec 2010 | A1 |
| 20110009715 | O'Reilly et al. | Jan 2011 | A1 |
| 20110054265 | Hafezi et al. | Mar 2011 | A1 |
| 20110065983 | Hafezi et al. | Mar 2011 | A1 |
| 20110077660 | Janik et al. | Mar 2011 | A1 |
| 20110124983 | Kroll et al. | May 2011 | A1 |
| 20110134906 | Garudadri et al. | Jun 2011 | A1 |
| 20110160549 | Saroka et al. | Jun 2011 | A1 |
| 20110224912 | Bhavaraju et al. | Sep 2011 | A1 |
| 20110230732 | Edman et al. | Sep 2011 | A1 |
| 20110270135 | Dooley et al. | Nov 2011 | A1 |
| 20120004520 | Whitworth et al. | Jan 2012 | A1 |
| 20120011699 | Hafezi et al. | Jan 2012 | A1 |
| 20120016231 | Westmoreland | Jan 2012 | A1 |
| 20120032816 | Cho et al. | Feb 2012 | A1 |
| 20120062371 | Radivojevic et al. | Mar 2012 | A1 |
| 20120071743 | Todorov et al. | Mar 2012 | A1 |
| 20120109112 | Strand et al. | May 2012 | A1 |
| 20120179004 | Roesicke et al. | Jul 2012 | A1 |
| 20120245043 | England | Sep 2012 | A1 |
| 20120276451 | Lestriez et al. | Nov 2012 | A1 |
| 20120299723 | Hafezi et al. | Nov 2012 | A1 |
| 20130030366 | Robertson et al. | Jan 2013 | A1 |
| 20130129869 | Hafezi et al. | May 2013 | A1 |
| 20130129872 | Kruger | May 2013 | A1 |
| 20130144132 | Hafezi et al. | Jun 2013 | A1 |
| 20130171596 | French | Jul 2013 | A1 |
| 20130172690 | Arne et al. | Jul 2013 | A1 |
| 20130185228 | Dresner | Jul 2013 | A1 |
| 20130193950 | Hafezi et al. | Aug 2013 | A1 |
| 20130196012 | Dill | Aug 2013 | A1 |
| 20130199662 | Gebbink | Aug 2013 | A1 |
| 20130209877 | Kren et al. | Aug 2013 | A1 |
| 20130223028 | Arne et al. | Aug 2013 | A1 |
| 20130275296 | Tietzen et al. | Oct 2013 | A1 |
| 20140066734 | Zdeblick | Mar 2014 | A1 |
| 20140179221 | Whitworth et al. | Jun 2014 | A1 |
| 20140180202 | Zdeblick et al. | Jun 2014 | A1 |
| 20140280125 | Bhardwaj et al. | Sep 2014 | A1 |
| 20140308930 | Tran | Oct 2014 | A1 |
| 20140349256 | Connor | Nov 2014 | A1 |
| 20140374276 | Guthrie et al. | Dec 2014 | A1 |
| 20150017486 | Lai | Jan 2015 | A1 |
| 20150059922 | Thompson et al. | Mar 2015 | A1 |
| 20150080677 | Thompson et al. | Mar 2015 | A1 |
| 20150080678 | Frank et al. | Mar 2015 | A1 |
| 20150080679 | Frank et al. | Mar 2015 | A1 |
| 20150080680 | Zdeblick et al. | Mar 2015 | A1 |
| 20150112243 | Hafezi et al. | Apr 2015 | A1 |
| 20150127737 | Thompson et al. | May 2015 | A1 |
| 20150127738 | Thompson et al. | May 2015 | A1 |
| 20150149375 | Thompson et al. | May 2015 | A1 |
| 20150150480 | Zdeblick et al. | Jun 2015 | A1 |
| 20150164746 | Costello et al. | Jun 2015 | A1 |
| 20150173646 | Berkman et al. | Jun 2015 | A1 |
| 20150223751 | Zdeblick et al. | Aug 2015 | A1 |
| 20150230729 | Zdeblick et al. | Aug 2015 | A1 |
| 20150248833 | Arne et al. | Sep 2015 | A1 |
| 20150352343 | Hafezi et al. | Dec 2015 | A1 |
| 20150361234 | Hafezi et al. | Dec 2015 | A1 |
| 20160033667 | Schmidt et al. | Feb 2016 | A1 |
| 20160174900 | Zdeblick et al. | Jun 2016 | A1 |
| 20160345906 | Johnson et al. | Dec 2016 | A1 |
| 20160380708 | Dua et al. | Dec 2016 | A1 |
| 20170000179 | Cheng et al. | Jan 2017 | A1 |
| 20170020182 | Schmidt et al. | Jan 2017 | A1 |
| 20170216569 | Hafezi et al. | Aug 2017 | A1 |
| 20170265813 | Zdeblick et al. | Sep 2017 | A1 |
| 20170274194 | Robertson et al. | Sep 2017 | A1 |
| 20170296799 | Hafezi et al. | Oct 2017 | A1 |
| 20180026680 | Shirvani et al. | Jan 2018 | A1 |
| 20180110441 | Frank et al. | Apr 2018 | A1 |
| 20180184698 | Arne et al. | Jul 2018 | A1 |
| 20180214048 | Zdeblick et al. | Aug 2018 | A1 |
| 20180229996 | Thompson | Aug 2018 | A1 |
| Number | Date | Country |
|---|---|---|
| 1588649 | Mar 2005 | CN |
| 1650844 | Aug 2005 | CN |
| 101795202 | Aug 2010 | CN |
| 10313005 | Oct 2004 | DE |
| 0344939 | Dec 1989 | EP |
| 0526166 | Feb 1993 | EP |
| 0981152 | Feb 2000 | EP |
| 1246356 | Oct 2002 | EP |
| 1534054 | May 2005 | EP |
| 1702553 | Sep 2006 | EP |
| 1244308 | Dec 2007 | EP |
| 2143369 | Jan 2010 | EP |
| 827762 | Feb 1960 | GB |
| 61072712 | Apr 1986 | JP |
| H01285247 | Nov 1989 | JP |
| 05228128 | Sep 1993 | JP |
| H11195415 | Jul 1999 | JP |
| 2000506410 | May 2000 | JP |
| 2002263185 | Sep 2002 | JP |
| 2002282219 | Oct 2002 | JP |
| 2003050867 | Feb 2003 | JP |
| 2004313242 | Nov 2004 | JP |
| 2005073886 | Mar 2005 | JP |
| 2005087552 | Apr 2005 | JP |
| 2005102959 | Apr 2005 | JP |
| 2005304880 | Apr 2005 | JP |
| 2005124708 | May 2005 | JP |
| 2005514966 | May 2005 | JP |
| 2005343515 | Dec 2005 | JP |
| 20055332328 | Dec 2005 | JP |
| 2006006377 | Jan 2006 | JP |
| 2006509574 | Mar 2006 | JP |
| 2007200739 | Aug 2007 | JP |
| 2007313340 | Dec 2007 | JP |
| 2009514870 | Apr 2009 | JP |
| 2009528909 | Aug 2009 | JP |
| 200600977523 | Jul 2006 | KR |
| 200406192 | May 2004 | TW |
| 200916136 | Apr 2009 | TW |
| WO1988002237 | Apr 1988 | WO |
| WO1992021307 | Dec 1992 | WO |
| WO1993008734 | May 1993 | WO |
| WO1993019667 | Oct 1993 | WO |
| WO1994001165 | Jan 1994 | WO |
| WO1997039963 | Oct 1997 | WO |
| WO1998043537 | Oct 1998 | WO |
| WO1999037290 | Jul 1999 | WO |
| WO1999059465 | Nov 1999 | WO |
| WO2001000085 | Jan 2000 | WO |
| WO2000032474 | Jun 2000 | WO |
| WO2000033246 | Jun 2000 | WO |
| WO2001047466 | Jul 2001 | WO |
| WO2001058236 | Aug 2001 | WO |
| WO2001074011 | Oct 2001 | WO |
| WO2001080731 | Nov 2001 | WO |
| WO2002000920 | Jan 2002 | WO |
| WO2002045489 | Jun 2002 | WO |
| WO2002058330 | Jul 2002 | WO |
| WO2002062276 | Aug 2002 | WO |
| WO2002087681 | Nov 2002 | WO |
| WO2002095351 | Nov 2002 | WO |
| WO2003005877 | Jan 2003 | WO |
| WO2003050643 | Jun 2003 | WO |
| WO2003068061 | Aug 2003 | WO |
| WO2004014225 | Feb 2004 | WO |
| WO2004019172 | Mar 2004 | WO |
| WO2004039256 | May 2004 | WO |
| WO2004066833 | Aug 2004 | WO |
| WO2004066834 | Aug 2004 | WO |
| WO2004066903 | Aug 2004 | WO |
| WO2004068881 | Aug 2004 | WO |
| WO2004075032 | Sep 2004 | WO |
| WO2004109316 | Dec 2004 | WO |
| WO2005011237 | Feb 2005 | WO |
| WO2005020023 | Mar 2005 | WO |
| WO2005024687 | Mar 2005 | WO |
| WO2005041438 | May 2005 | WO |
| WO2005047837 | May 2005 | WO |
| WO2005051166 | Jun 2005 | WO |
| WO2005053517 | Jun 2005 | WO |
| WO2005083621 | Sep 2005 | WO |
| WO2005110238 | Nov 2005 | WO |
| WO2005123569 | Dec 2005 | WO |
| WO2006021932 | Mar 2006 | WO |
| WO2006027586 | Mar 2006 | WO |
| WO2006028347 | Mar 2006 | WO |
| WO2006055892 | May 2006 | WO |
| WO2006055956 | May 2006 | WO |
| WO2006075016 | Jul 2006 | WO |
| WO2006100620 | Sep 2006 | WO |
| WO2006104843 | Oct 2006 | WO |
| WO2006116718 | Nov 2006 | WO |
| WO2006127355 | Nov 2006 | WO |
| WO2007001724 | Jan 2007 | WO |
| WO2007001742 | Jan 2007 | WO |
| WO2007013952 | Feb 2007 | WO |
| WO2007014084 | Feb 2007 | WO |
| WO2007014527 | Feb 2007 | WO |
| WO2007021496 | Feb 2007 | WO |
| WO2007027660 | Mar 2007 | WO |
| WO2007028035 | Mar 2007 | WO |
| WO2007036687 | Apr 2007 | WO |
| WO2007036741 | Apr 2007 | WO |
| WO2007036746 | Apr 2007 | WO |
| WO2007040878 | Apr 2007 | WO |
| WO2007067054 | Jun 2007 | WO |
| WO2007071180 | Jun 2007 | WO |
| WO2007096810 | Aug 2007 | WO |
| WO2007101141 | Sep 2007 | WO |
| WO2007115087 | Oct 2007 | WO |
| WO2007120946 | Oct 2007 | WO |
| WO2007127316 | Nov 2007 | WO |
| WO2007127879 | Nov 2007 | WO |
| WO2007128165 | Nov 2007 | WO |
| WO2007130491 | Nov 2007 | WO |
| WO2007143535 | Dec 2007 | WO |
| WO2007149546 | Dec 2007 | WO |
| WO2008008281 | Jan 2008 | WO |
| WO2008012700 | Jan 2008 | WO |
| WO2008030482 | Mar 2008 | WO |
| WO2008052136 | May 2008 | WO |
| WO2008063626 | May 2008 | WO |
| WO2008066617 | Jun 2008 | WO |
| WO2008076464 | Jun 2008 | WO |
| WO2008089232 | Jul 2008 | WO |
| WO2008091683 | Jul 2008 | WO |
| WO2008095183 | Aug 2008 | WO |
| WO2008097652 | Aug 2008 | WO |
| WO2008101107 | Aug 2008 | WO |
| WO2008112577 | Sep 2008 | WO |
| WO2008112578 | Sep 2008 | WO |
| WO2008120156 | Oct 2008 | WO |
| WO2008133394 | Nov 2008 | WO |
| WO2008134185 | Nov 2008 | WO |
| WO2008150633 | Dec 2008 | WO |
| WO2009000447 | Dec 2008 | WO |
| WO2009001108 | Dec 2008 | WO |
| WO2009006615 | Jan 2009 | WO |
| WO2009029453 | Mar 2009 | WO |
| WO2009031149 | Mar 2009 | WO |
| WO2009036334 | Mar 2009 | WO |
| WO2009051829 | Apr 2009 | WO |
| WO2009051830 | Apr 2009 | WO |
| WO2009063377 | May 2009 | WO |
| WO2009081348 | Jul 2009 | WO |
| WO2009111664 | Sep 2009 | WO |
| WO2009146082 | Dec 2009 | WO |
| WO2010009100 | Jan 2010 | WO |
| WO2010011833 | Jan 2010 | WO |
| WO2010019778 | Feb 2010 | WO |
| WO2010057049 | May 2010 | WO |
| WO2010080765 | Jul 2010 | WO |
| WO2010080843 | Jul 2010 | WO |
| WO2010107563 | Sep 2010 | WO |
| WO2010129288 | Nov 2010 | WO |
| WO2010132331 | Nov 2010 | WO |
| WO2010135516 | Nov 2010 | WO |
| WO2011068963 | Jun 2011 | WO |
| WO2011133799 | Oct 2011 | WO |
| WO2011159336 | Dec 2011 | WO |
| WO2011159337 | Dec 2011 | WO |
| WO2011159338 | Dec 2011 | WO |
| WO2011159339 | Dec 2011 | WO |
| WO2012112561 | Aug 2012 | WO |
| WO2015112603 | Jul 2015 | WO |
| WO2015112604 | Jul 2015 | WO |
| WO2015119911 | Aug 2015 | WO |
| Entry |
|---|
| AADE, “AADE 37th Annual Meeting San Antonio Aug. 4-7, 2010” American Association of Diabetes Educators (2010); http://www.diabeteseducator.org/annualmeeting/2010/index.html; 2 pp. |
| Arshak et al., A Review and Adaptation of Methods of Object Tracking to Telemetry Capsules IC-Med (2007) vol. 1, No. 1, Issue 1, 12pp. |
| “ASGE Technology Status Evaluation Report: wireless capsule endoscopy” American Soc. for Gastrointestinal Endoscopy (2006) vol. 63, No. 4; 7 pp. |
| Au-Yeung, K., et al., “A Networked System for Self-Management of Drug Therapy and Wellness”, Wireless Health '10, Oct. 5-7, 2010, San Diego, 9 pages. |
| Aydin et al., “Design and implementation considerations for an advanced wireless interface in miniaturized integrated sensor Microsystems” Sch. of Eng. & Electron., Edinburgh Univ., UK; (2003); abstract. |
| Bohidar et al., “Dielectric Behavior of Gelatin Solutions and Gels” Colloid Polym Sci (1998) 276:81-86. |
| Carlson et al., “Evaluation of a non-invasive respiratory monitoring system for sleeping subjects” Physiological Measurement (1999) 20(1): 53. |
| Coury, L. “Conductance Measurement Part 1: Theory”; Current Separations, 18:3 (1999) p. 91-96. |
| Delvaux et al., “Capsule endoscopy: Technique and indications” Clinical Gastroenterology (2008) vol. 22, Issue 5, pp. 813-837. |
| Dhar et al., “Electroless nickel plated contacts on porous silicon” Appl. Phys. Lett. 68 (10) pp. 1392-1393 (1996). |
| Eldek A., “Design of double dipole antenna with enhanced usable bandwidth for wideband phased array applications” Progress in Electromagnetics Research PIER 59, 1-15 (2006). |
| Ferguson et al., “Dielectric Constant Studies III Aqueous Gelatin Solutions” J. Chem. Phys. 2, 94 (1934) p. 94-98. |
| Furse C. M., “Dipole Antennas” J. Webster (ed). Wiley Encyclopedia of Electrical and Electronics Engineering (1999) p. 575-581. |
| Gaglani S. “Put Your Phone, or Skin, on Vibrate” MedGadget (2012) http://medgadget.com/2012/03/put-your-phone-or-skin-on-vibrate.html 8pp. |
| Gilson, D.R. “Molecular dynamics simulation of dipole interactions”, Department of Physics, Hull University, Dec. 2002, p. 1-43. |
| Given Imaging, “Agile Patency Brochure” (2006) http://www.inclino.no/documents/AgilePatencyBrochure_Global_GMB-0118-01.pdf; 4pp. |
| Gonzalez-Guillaumin et al., “Ingestible capsule for impedance and pH monitoring in the esophagus” IEEE Trans Biomed Eng. (2007) 54(12): 2231-6; abstract. |
| Greene, “Edible RFID microchip monitor can tell if you take your medicine” Bloomberg Businessweek (2010) 2 pp.; http://www.businessweek.com/idg/2010-03-31/edible-rfid-microchip-monitor-can-tell-if-you-take-your-medicine.html. |
| Heydari et al., “Analysis of the PLL jitter due to power/ground and substrate noise”; IEEE Transactions on Circuits and Systems (2004) 51(12): 2404-16. |
| Hoover et al., “Rx for health: Engineers design pill that signals it has been swallowed” University of Florida News (2010) 2pp.; http://news.ufl.edu/2010/03/31/antenna-pill-2/. |
| INTROMEDIC, MicroCam Innovative Capsule Endoscope Pamphlet. (2006) 8 pp (http://www.intromedic.com/en/product/productinfo.asp). |
| ISFET—Ion Sensitive Field-Effect Transistor; Microsens S.A. pdf document. Office Action dated Jun. 13, 2011 for U.S. Appl. No. 12/238,345; 4pp. |
| Jung, S. “Dissolvable ‘Transient Electronics’ Will Be Good for Your Body and the Environment” MedGadget; Oct. 1, 2012; Onlne website: http://medgadget.com/2012/10/dissolvable-transient-electronics-will-be-good-for-your-body-and-the-environment.html; downloaded Oct. 24, 2012; 4 pp. |
| Juvenile Diabetes Research Foundation International (JDRF), “Artificial Pancreas Project” (2010); http://www.artificialpancreasproject.com/; 3 pp. |
| Kamada K., “Electrophoretic deposition assisted by soluble anode” Materials Letters 57 (2003) 2348-2351. |
| Kendle, Earl R. and Morris, Larry A., “Preliminary Studies in the Development of a Gastric Battery for Fish” (1964). Nebraska Game and Parks Commission White Papers, Conference Presentations, & Manuscripts. Paper 22. p. 1-6. |
| Kim et al., “A Semi-Interpenetrating Network System for a Polymer Membrane”; Eur. Polym. J. vol. 33 No. 7; pp. 1009-1014 (1997). |
| Li, P-Y, et al. “An electrochemical intraocular drug delivery device”, Sensors and Actuators A 143 (2008) p. 41-48. |
| LIFESCAN, “OneTouch UltraLink™”http://www.lifescan.com/products/meters/ultralink (2010) 2 pp. |
| MacKay et al., “Radio Telemetering from within the Body” Inside Information is Revealed by Tiny Transmitters that can be Swallowed or Implanted in Man or Animal Science (1991) 1196-1202; 134; American Association for the Advancement of Science, Washington D.C. |
| MacKay et al., “Endoradiosonde” Nature, (1957) 1239-1240, 179 Nature Publishing Group. |
| McKenzie et al., “Validation of a new telemetric core temperature monitor” J. Therm. Biol. (2004) 29(7-8):605-11. |
| MEDTRONIC, “CareLink Therapy Management Software for Diabetes” (2010); https://carelink.minimed.com/patient/entry.jsp?bhcp=1; 1 pp. |
| MEDTRONIC, “Carelink™ USB” (2008) http://www.medtronicdiabetes.com/pdf/carelink_usb_factsheet.pdf 2pp. |
| MEDTRONIC “The New MiniMed Paradigm® Real-Time Revel™ System” (2010) http://www.medtronicdiabetes.com/products/index.html; 2 pp. |
| MEDTRONIC, “Mini Med Paradigm® Revel™ Insulin Pump” (2010) http://www.medtronicdiabetes.com/products/insulinpumps/index.html; 2 pp. |
| MEDTRONIC, Mini Med Paradigm™ Veo™ System: Factsheet (2010). http://www.medtronic-diabetes.com.au/downloads/Paradigm%20Veo%20Factsheet.pdf ; 4 pp. |
| Mojaverian et al., “Estimation of gastric residence time of the Heidelberg capsule in humans: effect of varying food composition” Gastroenterology (1985) 89:(2): 392-7. |
| O'Brien et al., “The Production and Characterization of Chemically Reactive Porous Coatings of Zirconium Via Unbalanced Magnetron Sputtering” Surface and Coatings Technology (1996) 86-87; 200-206. |
| Park, “Medtronic to Buy MiniMed for $3.7 Billion” (2001) HomeCare; http://homecaremag.com/mag/medical_medtronic_buy_minimed/; 2 pp. |
| Radio Antennae, http://www.erikdeman.de/html/sail018h.htm; (2008) 5 pages. |
| Rolison et al., “Electrically conductive oxide aerogels: new materials in electrochemistry” J. Mater. Chem. (2001) 1, 963-980. |
| Roulstone, et al., “Studies on Polymer Latex Films: I. A study of latex film morphology” Polymer International 24 (1991) pp. 87-94. |
| Sanduleanu et al., “Octave tunable, highly linear, RC-ring oscillator with differential fine-coarse tuning, quadrature outputs and amplitude control for fiber optic transceivers” (2002) IEEE MTT-S International Microwave Symposium Digest 545-8. |
| Santini, J.T. et al, “Microchips as controlled drug delivery-devices”, Agnew. Chem. Int. Ed. (2000), vol. 39, p. 2396-2407. |
| “SensiVida minimally invasive clinical systems” Investor Presentation Oct. 2009 28pp; http://www.sensividamedtech.com/SensiVidaGeneralOctober09.pdf. |
| Shawgo, R.S. et al. “BioMEMS from drug delivery”, Current Opinion in Solid State and Material Science 6 (2002), p. 329-334. |
| Shin et al., “A Simple Route to Metal Nanodots and Nanoporous Metal Films”; Nano Letters, vol. 2, No. 9 (2002) pp. 933-936. |
| “Smartlife awarded patent for knitted transducer” Innovation in Textiles News: http://www.innovationintextiles.com/articles/208.php; 2pp. (2009). |
| Solanas et al., “RFID Technology for the Health Care Sector” Recent Patents on Electrical Engineering (2008) 1, 22-31. |
| Soper, S.A. et al. “Bio-Mems Technologies and Applications”, Chapter 12, “MEMS for Drug Delivery”, p. 325-346 (2007). |
| Swedberg, “University Team Sees Ingestible RFID Tag as a Boon to Clinical Trials” RFID Journal Apr. 27, 2010; http://www.rfidjournal.com/article/view/7560/1 3pp. |
| Tajalli et al., “Improving the power-delay performance in subthreshold source-coupled logic circuits” Integrated Circuit and System Design. Power and Timing Modeling, Optimization and Simulation, Springer Berlin Heidelberg (2008) 21-30. |
| Tatbul et al., “Confidence-based data management for personal area sensor networks” ACM International Conference Proceeding Series (2004) 72. |
| Tierney, M.J. et al “Electroreleasing Composite Membranes for Delivery of Insulin and other Biomacromolecules”, J. Electrochem. Soc., vol. 137, No. 6, Jun. 1990, p. 2005-2006. |
| Trutag Technologies, Inc., Spectral Microtags for Authentication and Anti-Counterfeiting; “Product Authentication and Brand Protection Solutions”; http://www.trutags.com/; downloaded Feb. 12, 2013; 1 pp. |
| Walkey, “MOSFET Structure and Processing”; 97.398* Physical Electronics Lecture 20; 24 pp. |
| Wang, X. et al “Resistance to Tracking and Erosion of Silicone Rubber Material under Various Types of Precipitation”, Jpn. J. Appl. Phys. vol. 38 (1999) pp. 5170-5175. |
| Watson, et al., “Determination of the relationship between the pH and conductivity of gastric juice” Physiol Meas. 17 (1996) pp. 21-27. |
| Winter, J. et al. “The material properties of gelatin gels”; USA Ballistic Research Laboratories, Mar. 1975, p. 1-157. |
| Wongmanerod et al., “Determination of pore size distribution and surface area of thin porous silicon layers by spectroscopic ellipsometry” Applied Surface Science 172 (2001) 117-125. |
| Xiaoming et al., “A telemedicine system for wireless home healthcare based on bluetooth and the internet” Telemedicine Journal and e-health (2004) 10(S2): S110-6. |
| Yang et al., “Fast-switching frequency synthesizer with a discriminator-aided phase detector” IEEE Journal of Solid-State Circuits (2000) 35(10): 1445-52. |
| Zimmerman, “Personal Area Networks: Near-field intrabody communication” IBM Systems Journal (1996) 35 (3-4):609-17. |
| Zworkin, “A Radio Pill” Nature, (1957) 898, 179 Nature Publishing Group. |
| Target Innovations, Tablet Metal Detector, https ://web. arch ive.org/web/20 130215063351/http://www. metaldetectorindia.com/tablet -metal-detector. html, Feb. 15, 2013, 2 pg. |
| TargetPharmaceutical Metal Detector, Feb. 15, 2013 downloaded from Target Innovations, Tablet Metal Detector, Feb. 15, 2013, 1 pg. |
| Youtube video Pharmaceutical Metal Detector/Tablet Metal Detector/ Capsule Metal Detector/ Dry Fruits; https://www.youtube.com/watch?v=l0126txam_s, May 12, 2012. |
| Number | Date | Country | |
|---|---|---|---|
| 20170014046 A1 | Jan 2017 | US |
| Number | Date | Country | |
|---|---|---|---|
| 61173511 | Apr 2009 | US | |
| 61173564 | Apr 2009 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 13756280 | Jan 2013 | US |
| Child | 15050733 | US | |
| Parent | 12744642 | US | |
| Child | 13756280 | US |
